

AWARD NUMBER: W81XWH-18-1-0077

TITLE: Neural Crest Origin of TSC Tumors

PRINCIPAL INVESTIGATOR: Jeanine D'Armiento

CONTRACTING ORGANIZATION: Columbia University, New York, NY

REPORT DATE: September 2022

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE September 2022		2. REPORT TYPE Final		3. DATES COVERED 01Jun2018 — 31May2022	
4. TITLE AND SUBTITLE Neural Crest Origin of TSC Tumors				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-18-1-0077	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Jeanine D'Armiento, MD, PhD E-Mail: jmd12@cumc.columbia.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Trustees of Columbia University In the City of New York Health Sciences Division 630 West 168 th Street New York, NY 10032				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Given the multi-organ manifestation of TS lesions, and the mesenchymal lineage of tumors recovered from TS patients, it has been postulated that TS is a neurocristopathy in which tumorigenesis is initiated by neural crest cells, but direct supporting experimental evidence has not been produced. We hypothesize that <u>by tracking neurocristogenesis in a TSC2^{+/-} mouse model, we will delineate the molecular mechanisms underlying temporal ontogenesis and progression of benign neoplasms characterizing TS and LAM. Furthermore, we hypothesize that HMGA2 misexpression defines tumorigenesis in TS and LAM caused by differentiating neural crest progenitor cells. This will subsequently lead to novel therapeutic approaches to the disease. Aim 1: To delineate the biochemical signaling that determines the temporal sequence of neural crest cell-induced initiation and progression of tumors using a TSC2^{+/-} mouse model. Aim 2: To determine the role of HMGA2 in tumor pathogenicity driven by TSC2-haploinsufficient iPSC-derived neural crest precursors.</u>					
15. SUBJECT TERMS None listed.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 33	19a. NAME OF RESPONSIBLE PERSON USAMRDC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	1
2. Keywords	1
3. Accomplishments	1
4. Impact	7
5. Changes/Problems	8
6. Products	8
7. Participants & Other Collaborating Organizations	9
8. Special Reporting Requirements	10
9. Appendices	10

INTRODUCTION:

Tuberous Sclerosis (TS) is a genetic disorder caused by inactivating mutations in either Tsc1/2 tumor suppressor genes leading to dysregulation of cellular differentiation, migration, proliferation during tissue development causing hamartomatous lesions, cysts, and tubers in almost every organ in the body. The origin of tumorigenic cells in TS is not known, and the biochemical signals initiating onset and progression of tumors has not been delineated. Given the prevalence of TS at 1 in 6,000 births, and the potential that the disorder is under-diagnosed with significant phenotype under-recognition and no known cure, the need for comprehensive understanding of the pathophysiology of the disease cannot be overemphasized. The marked variability and multi-systemic occurrence of TS symptoms, and the heterogeneity in tissue composition of TS neoplasms biased towards a mesenchymal phenotype, informed our hypothesis that tuberous sclerosis is a neurocristopathy. Proposed studies test this hypothesis by tracking and analyzing tumor development in a Tsc2^{+/-} reporter mouse model whose neural crest cells are genetically labeled with a fluorophore, and by recapitulating germline and somatic mutations during neurocristogenesis using induced pluripotent stem cells (iPSCs). This report summarizes our progress and findings thus far.

KEYWORDS:

mTOR, Neurocristogenesis, High Mobility Group AT-Hook 2 (HMGA2), Induced Pluripotent Stem Cells (iPSCs), Tumorigenesis

ACCOMPLISHMENTS:

What were the major goals of the project?

There are two major goals for this project. The first goal was to determine the molecular signals governing the onset and progression of tumors whose development is initiated by neural crest cells using a Tsc2^{+/-} reporter mouse model. This aim was completed, and we have published the studies this year.

Our second goal was to recapitulate a tuberous sclerosis disease state by differentiating induced pluripotent stem cells (iPSCs) into neural crest cells and engineering inactivating and overexpressing genetic mutations in *Hmga2* and *Tsc2* to assess the role of the interaction between these two genotypes in tumorigenesis using a cell culture-based system. We are generated and characterized iPSC colonies from peripheral blood mononuclear cells (PBMCs) of TSC patients and assessed the pluripotency of the line (40% of the milestone has been completed). We have performed differentiation studies into neural crest progenitor cells and assessed proliferation and cell invasion in these cells. We also were able to perform RNA Sequencing analysis to further define the mechanism of tumor formation from the neural crest derived tumors.

1. What was accomplished under these goals?

The following is the SOW with completion dates:

Specific Aim 1: To delineate the biochemical signaling that determines the temporal sequence of neural crest cell-induced initiation and progression of tumors using a TSC2 ^{+/-} mouse	Timeline	Date Complete
Task 1: Tracking Temporal Ontogenesis of Tumors in TSC ^{+/-} mice	Months	

Mating Gt(ROSA)26Sor ^{tm9(CAG-tdTomato)Hze/J} X Tg(MPZ- Cre)26Mes/J and generation of progeny (This task has been initiated using funds from the Lisa Dean Moseley Foundation Award)	0	September 2018
Backcrossing MPZ-Cre ^{R26R} X Gt(ROSA)26Sor ^{tm9(CAG-tdTomato)Hze/J} and generation of progeny (This task has been initiated using funds from the Lisa Dean Moseley Foundation Award)	0	October 2018
Obtain ACURO approval	3	October 2018
Mating MPZ-Cre ^{R26R} X TSC2 ^{+/-} mice and generation of progeny	4-10	December 2018- March 2019
Detection of tumors and bi-weekly monitoring of tumor development	8-20	March 2019- January 2021
Milestone(s) Achieved: Identification of timing of onset and progression of tumors in TSC2 ^{+/-} MPZ-Cre ^{R26R} transgenic reporter mouse		June 2022
Local IRB/IACUC Approval: AC-AAAR3401		September 2018
Task 2: Single Cell RNA Sequencing of tumorigenic cells in TSC^{+/-} mice		
Excise organ-specific tissues and tumors, dissociate cells and sort dsRed ⁺ expressing cells using flow cytometry	9-20	December 2018 May 2019
Single Cell RNA Sequencing of sorted dsRed-expressing cells; immunocytochemistry	11-24	January 2022
Analysis of RNA Sequencing data using R, and Ingenuity Pathway Analysis (IPA); Manuscript preparation	20-32	March 2022
Milestone(s) Achieved: Delineating molecular signaling governing ontogenesis and progression of tumors		August 2022
Specific Aim 2: To determine the role of HMGA2 in tumor pathogenicity driven by TSC2-haploinsufficient iPSC-derived neural crest		
Delineating molecular signaling governing HMGA2-mediated tumorigenesis		
Obtain HRPO approval	3	September 2018
Sub-culturing skin fibroblasts from de-identified tissue samples	4-7	June 2019

Derivation of iPSCs from skin fibroblasts	6-10	July 2019 January 2020
iPSC characterization and assessment of pluripotency	8-12	October 2019 February 2020
iPSC differentiation into neural crest progenitors (NCC) using feeder-free system of Noggin and SB431542 (NSB); Propagation of iPSC-NCC in culture	12-18	March 2021
Antibody mediated isolation of CD57 ⁺ /AP2 α ⁺ , CD57 ⁺ /AP2 α ⁻ , CD57 ⁻ /AP2 α ⁻ iPSC-NCCs using flow cytometry; Propagation of cells in culture	16-20	May 2021
Cloning HMGA2 cDNA into pcDNA3.1(+); transfection of constructs into iPSC-NCCs by electroporation; Propagation of cell cultures	20-26	January 2022
Transfection of U6gRNA TSC2-Cas9 and non-target guide control into iPSC-NCCs by electroporation; Propagation of cell cultures	22-28	March 2022
Analysis of RNA Sequencing data using R, and Ingenuity Pathway Analysis (IPA); Manuscript preparation	26-34	August 2022
Milestone(s) Achieved: Identified HMGA2 pathway targets mediating tumorigenesis in TSC2 ^{+/-} mice; delineate interaction between HMGA2 and mTOR pathway targets		August 2022

In specific Aim 1, we tracked temporal ontogenesis of tumors in Tsc2^{+/-} reporter mice and performed single cell RNA sequencing of renal and hepatic tumor extracts at onset of tumorigenesis and at defined timepoints through the course of tumor growth. In doing so, we were able to illuminate genetic and biochemical changes that initiate tumor incidence and growth thereby recapitulating the pathophysiology of tumors in TS.

Tumor tracking in the Tsc2^{+/-} reporter mice was performed beginning at 2 months of age at weekly intervals using sequential IVIS spectral imaging detecting tdTomato excitation/emission spectra at 570nm/620nm, and small animal ultrasound. Small animal MRI imaging was used to confirm sites of tumor development prior to excision for subsequent analysis. **Figure 1B** displays results of IVIS spectral imaging of an array of age-matched littermate progeny of the selected genotypes used in this study showing tdTomato epifluorescence to be perceptibly brightest in the abdominal region of only the Tsc2^{+/-}/Mp α (Cre)/TdT^{fl/fl} mice. Spectral quantification of tdTomato epifluorescence revealed significantly higher average radiant efficiency measurements (p=0.0001*) in Tsc2^{+/-}/Mp α (Cre)/TdT^{fl/fl} mice compared to other mouse genotypes in two different sets of mice imaging studies (**Figure 1C**). TS tumorigenesis in this select mouse group was further verified by ultrasound imaging revealing the occurrence of tumors in the kidneys of Tsc2^{+/-}/Mp α (Cre)/TdT^{fl/fl} mice (**Figure D2**) compared to tumor-less renal tissue in the Tsc2^{+/-}/Mp α (Cre)/TdT^{fl/fl} mice (**Figure D1**) and Tsc2^{+/+}/Mp α (Cre)/TdT^{+/+} mice (not shown). High-resolution magnetic resonance imaging further confirms the occurrence of bilateral cortical tumor growth in both kidneys of Tsc2^{+/-}/Mp α (Cre)/TdT^{fl/fl} mice (**Figure 1E**). Tsc2^{+/-}/Mp α (Cre)/TdT^{+/+} mice spontaneously developed renal tumors which could not be detected by tdTomato epifluorescence.




Figure 1: Generation of Tuberous Sclerosis Reporter Mouse Model and Imaging Techniques for Visualizing TS tumors – A) Schematic of genetic crosses to generate *Tsc2*^{+/-} reporter mouse models show floxed *R26Sor^{tm9}(CAG-tdTomato)^{Hze}* mice (n=10 animals) were crossed with Tg(Mpz-Cre)26Mes mice (n=10 animals) expressing Cre recombinase under the control of myelin protein zero (MPZ) promoter. *Mpz(Cre)*^{tm1.1JDar} mouse progeny (n=8 animals) were then

mated with *Tsc2*^{+/-} mice (n=10 animals) to source *Tsc2*^{+/-} *Mpz(Cre)*^{fl/fl} tuberous sclerosis reporter mouse models (shown in red) that spontaneously develop renal tumors driven by neural crest cells labeled with tdTomato. **B)** IVIS spectral images of abdominopelvic cavities of 1.3yr old *Tsc2*^{+/-} *Mpz(Cre)*^{fl/fl} tuberous sclerosis mouse model compared to age-matched *Tsc2*^{+/-} *Mpz(Cre)* *TdTomato*^{+/+}, *Tsc2*^{+/-} *Mpz(Cre)* *TdTomato*^{fl/fl}, and *Tsc2*^{+/-} *Mpz(Cre)* *TdTomato*^{+/+} mice showing epifluorescence of tdTomato-expressing regions (n=4 mice/genotype). **C)** Average radiant efficiency was used to compare tdTomato epifluorescence in these mouse models by one-way ANOVA and post-hoc Dunnett's test (p=0.0001*). Small animal ultrasound scan of normal kidney (NK) parenchyma of adult mice wildtype for the *Tsc2* gene (**D1**) in comparison to the kidneys in *Tsc2*^{+/-} *Mpz(Cre)*^{fl/fl} mice (**D2**) with highlighted sites of tumors (T). BV denotes blood vessels. Rapid magnetic resonance images of kidneys (**E**) in *Tsc2*^{+/-} *Mpz(Cre)* *TdTomato*^{fl/fl} mice identifying tumors (T), shown with arrows and dashes.

Renal Tumorigenesis in *Tsc2*^{+/-} mice Correlate with Onset and Proliferation of Neural Crest Precursor Populations

Prior to our study, the earliest reported detection of renal neoplasms in tuberous sclerosis *Tsc2*^{+/-} mouse models was 6 months of age, and earlier polycystic lesions occurring in the *Dermo1^{Cre};Tsc2^{fl/fl}* mice led to mouse lethality by 3 weeks of age. We report the earliest known detection of ectopic fluid-filled renal cysts in *Tsc2*^{+/-} */Mpz(Cre)* */TdTomato*^{fl/fl} by 4 months of age (**Figure 2A**). These tumors were detectable by both IVIS spectral imaging and ultrasound. By 6 months of age, multiple solid tumors and/or cysts containing denser fluid can be observed (**B**), and by 16 months, enlarged, dysmorphic, inflamed renal tissue coalescing with multiple cysts can be observed (C). *Tsc2*^{+/-} mice renal tumors were excised at 4, 6 and 16 months and dissociated into single cell populations for flow cytometric sorting of tdTomato⁺ neural crest cells in these tumors. Results indicate that the significant increase in renal tumor volume (**D**) and number of tumors (**E**) in *Tsc2*^{+/-} */Mpz(Cre)* */TdTomato*^{fl/fl} mice over the 16-month period correlated with a marked increase in the fraction of gated tdTomato⁺ cells from an average of 0.22% beginning at 6 months to 2% at 16 months (**Figure 1F**) compared to sorted cells from *Tsc2*^{+/-} */Mpz(Cre)* */TdTomato*^{+/+} and *Tsc2*^{+/-} */Mpz(Cre)* */TdTomato*^{fl/fl} mice after gating protocols for live cells (DAPI) and Texas Red (TR). Representative dot plots comparing gating results of flow cytometric separation of renal tissue and tumor cells between *Tsc2*^{+/-} */Mpz(Cre)* */TdTomato*^{fl/fl} and *Tsc2*^{+/-} */Mpz(Cre)* */TdTomato*^{fl/fl} obtained at 4 months (**G,H**), 6 months (**I,J**) and 16 months (**K,L**) respectively are displayed. Single cell suspensions of cranial neural crest cells (CNCCs) (**M**) and trunk neural crest cells (TNCCs) (**N**) excised from 9.5dpc *Tsc2*^{+/-} *Mpz(Cre)* *TdTomato*^{fl/fl} mice embryos were used as positive controls to assess the emergence of tdTomato⁺ neural crest cells in tuberous sclerosis mice. The resolution of tdTomato⁺ cells in renal tumor cell dissociates indicates active *Mpz* promoter activity in cells of a neural crest lineage. We believe this unique cell population are migrants from the neural crest that retain their proliferative and stem cell character and differentiate to source pathogenic tumor cells of TS as phenotypic manifestations of mono-allelic and bi-

allelic mutations at the *Tsc2* gene locus. Although the fraction of these tdTomato-expressing cells in both the gated and whole cell populations analyzed by flow cytometry is quite low, they are proportional in quantity to the neural crest cell precursors obtained from 9.5dpc embryonic cranial tissue and mesodermal somites used to obtain our cranial and trunk neural crest cell controls respectively.




Figure 2: Identification of Neural Crest Lineage Cells in Ectopic Renal Tumor Onset of the *Tsc2*^{+/-} mice – A) Earliest reported detection of ectopic renal tumors in the *Tsc2*^{+/-}*Mpz(Cre)TdT^{fl/fl}* mice begins at 4 months of age (A) then pictured at 6 months (B) and at 16 months (C). Tumor volume (D) and number (E) increased proportionally during the same period. Tumors from *Tsc2*^{+/-} *Mpz(Cre)TdT^{fl/fl}* mice were

dissociated, gated for live/dead staining (Sytox Green/DAPI) and sorted for tdTomato expression in comparison with renal cortical cells obtained from age-matched *Tsc2*^{+/-} *Mpz(Cre)TdT^{fl/fl}* (F). Results showed proportional increase in tdTomato(+) cells with increase in mice age, tumor volume and number of tumors. Representative flow cytometric data for comparing single cell events obtained between renal cortical tissue and TS reporter mice at 4 months (G,H), 6 months of age (I,J), and 16 months (K,L) are displayed respectively. Single cell suspensions of cranial neural crest cells (CNCCs) (M) and trunk neural crest cells (TNCCs) (N) excised from the 9.5dpc *Tsc2*^{+/-}*Mpz(Cre)TdT^{fl/fl}* mice embryos were used as positive controls to assess the emergence of tdTomato+ neural crest cells in tuberous sclerosis mice. Flow cytometric data is one representative experiment of doublet studies performed at different times using N=2 mice/genotype/study. Acquisition and analyses of flow cytometric data was performed on a Bio-Rad S3e cell sorter and analyzed using FCS Express 7 Plus software.

For specific aim 2, we have isolated peripheral blood mononuclear cells (PBMCs) obtained from six patients with clinical diagnosis of TSC and reprogrammed them into iPSC clones (N=4 clones per patient). We have confirmed their pluripotency using marker expression biology and performed G-band karyotype analysis to assess the presence of chromosomal abnormalities. We also intend to employ the same iPSC reprogramming paradigm using fibroblasts dissociated from biopsies of cutaneous angiofibromas similarly diagnostic of TSC biopsies. To characterize the genotypic identity of iPSC clones, we have determined loss of heterozygosity (LOH) status for each clone in the TSC locus and selected three iPSC clones per patient sample for use in further experimentation based on the presence or absence of LOH. We also sequenced the DNA from these clones for identification of single nucleotide polymorphisms (SNP) mutations in the TSC coding region (42 exons). In the last year we have been able to identify TSC mutations in these cells even when DNA from the PBMCs did not demonstrate a mutation. When utilizing iPSC clones from healthy patients and patients with diseases not associated with LAM no TSC mutations were identified.

Single Cell Transcriptomic Analysis annotates neural crest cells in *Tsc2*^{+/-} Mice Renal Tumors. A total of 6708 *Tsc2*^{+/-}*Mpz(Cre)TdT^{fl/fl}* mouse renal tumor cells were analyzed using the 10x Genomics Cell Ranger pipeline with 52,657 mean reads per cell. Fourteen cell clusters were identified by significant log2Fold Change and q-values (<0.05). scRNA-seq alignment and quantification was performed by comparison with: GRCm38 mm10 mouse reference genome and publicly available E8.5 & E20.5 stage embryonic neural tissue from C57BL/6J mice. Canonical neural crest markers including *Tfap2*, *Hoxa7*, *Hoxb9* were used to annotate neural crest cell clusters seen as 9 & 11 (Figure 3).





Figure 3. Single Cell Transcriptomic Analysis of TSC tumors in *Tsc2*^{-/-}*Mpz*(*Cre*)*TdY*^{fl/fl} mice.

Post-hoc sctransform analysis using Seurat in R was used to identify top 5 differentially expressed genes in clusters 9 and 11. Select novel genes including *Sox9*, *Lcn2*, *Wfdc2*, *Clu*, *Ndr1* were expressed at 2-8-fold higher magnitude than canonical neural crest markers. Expression of the select neural crest markers significantly increased in *Tsc2*^{+/-} mice kidney tumors (KT) compared to normal kidney cortical tissues (NK) with mice age (**Figure 4**).

Gene Name	Gene	Cluster	Fold Change	p-Adj
Keratin 18	Krt18	9	3.17	0
Polymeric immunoglobulin receptor	Pigr	9	3.04	0
Lipocalin-2	Lcn2	9	3.54	8.80E-291
WAP Four-Disulfide Core Domain	Wfdc2	9	3.41	2.91E-266
Clusterin	Clu	9	3.43	1.98E-215
Glutathione Peroxidase 3	Gpx3	11	1.40	2.55E-80
FXD Domain Containing Ion Transport Regulator 2	Fxyd2	11	1.50	9.38E-71
SRY-Box Transcription Factor 9	Sox9	11	2.29	7.69E-240
N-Myc Downstream Regulated 1	Ndr1	11	2.98	3.27E-163
Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 10	Chchd10	11	2.00	1.76E-151




Figure 4. Differentially expressed neural crest markers in *Tsc2*^{+/-} mice kidney tumors, include *Lcn2* and *Sox9*.

This study provides evidence for an ontogenetic neural crest cellular lineage for *Tsc2*^{+/-} mice renal tumors with implications for the TS and LAM human disorders. Sub-populations of neural crest cells exist in masses within *Tsc2*^{+/-} mice renal neoplasms (and also in hepatic tumors). Multi-organ loci of tumorigenic neural crest cells and their selective gene expression states confirms that these tumor cells are post-migratory cranial neural crest relics of neurocristogenesis that co-opt tumorigenesis in their domiciled organs due to germline, somatic *Tsc2* mutations or environmental stimuli. Neural crest cells exhibit an increase in proliferation with tumor volume, multiplicity, and mice age akin to reported multi-potent self-renewal capacity of neural crest cells even in adulthood. These studies were published in iScience (iScience. 2021 Jun 4;24(7):102684).

To further these studies and in combination with the studies described in Aim 2 studies were performed for Single Cell Transcriptomic Analysis. 4.5% and 27.6% of dissociated control mice renal cells and *Tsc2*^{+/-} mice renal tumor cells were annotated as NCCs respectively. Top ranked significantly expressed NCC canonical oncogenes including secreted phosphoprotein 1 (*Spp1*, 94% of NCCs), Clusterin (*Clu*, 67% of NCCs), and Lipocalin-2 (*Lcn2*, 25% of NCCs). Expression of the *Spp1* gene in *Tsc2*^{+/-} mice renal tumor NCCs increased 100-fold compared to mouse renal tissues.

Analysis of the human samples demonstrated that *Spp1* exhibited the most robust expression compared to other candidate oncogenes, increased with aging *Tsc2*^{+/-} mice renal tumors (6 to 16 months), increased in LAM patient whole blood (N=8) compared to healthy patient (N=5) blood samples (*p<0.0001), and also

in LAM patient uterine neoplasms (N=6) compared to healthy uterine tissue (N=5) (*p<0.0001). *Spp1* gene expression was also significantly higher in renal angiomyolipomas (N=4 patients) compared to normal human renal tubular cells (N=3 individuals) (*p<0.0001).

These studies are being prepared for a manuscript to be submitted, Unachukwu, U and D'Armiento, J Defining the Pathogenic Role of Neural Crest Cells in Lymphangiomyomatosis: Mechanistic and Therapeutic Implications, manuscript in preparation.

2. What opportunities for training and professional development has the project provided?

This project has enabled the training of an Associate Research Scientist (ARS), Uchenna Unachukwu, under mentorship of the Principal Investigator, Dr. Jeanine D'Armiento, in skills including iPSC reprogramming, sanger sequencing and SNP mutational analysis, mouse breeding, mating and genotyping protocols, and in the reporting of experiments for presentations. Uchenna was accepted as a speaker at the 2021 International TSC and LAM Research Conference to present the described work and the presentation was given virtually. He has submitted an abstract to the American Thoracic Society International Conference 2023.

○ How were the results disseminated to communities of interest?

The first portion of the work was published in iScience (iScience. 2021 Jun 4;24(7):102684) and the second portion of the studies are in preparation for submission.

○ What do you plan to do during the next reporting period to accomplish the goals?

We are in a no cost extension and are finalizing the work for publication on the second Aim.

3. IMPACT:

○ What was the impact on the development of the principal discipline(s) of the project?

The major impact from this study is demonstrating the stem cell nature of the tumors in the TSC heterozygous mice. This finding is critical in demonstrating that stem cells are important in the pathogenesis of LAM and have opened a new avenue of investigation in the disease. Furthermore, the single cell transcriptomic analysis have identified unique genes expressed in the LAM stem cells that will allow us to target the LAM cell and open up novel treatment options.

The DNA sequencing and SNP mutational analysis of iPSC clones conclusively demonstrated the presence of TSC mutations in the iPSC cells of all patients including those with sporadic LAM. These findings not only strengthen the literature demonstrating the importance of TSC in this disease but suggest that the cells may be more susceptible to mutations during the process of reprogramming similar to what occurs during development in the patients. Future studies will examine this hypothesis.

○ What was the impact on other disciplines?

Nothing to Report

○ What was the impact on technology transfer?

Nothing to Report

-
- **What was the impact on society beyond science and technology?**

Nothing to Report

4. **CHANGES/PROBLEMS:**

- **Changes in approach and reasons for change**

There have been no changes to the project.

- **Actual or anticipated problems or delays and actions or plans to resolve them**

No issues in the last funding period.

- **Changes that had a significant impact on expenditures**

Nothing to Report

- **Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

-

Nothing to Report

- **Significant changes in use or care of human subjects**

Nothing to Report

- **Significant changes in use or care of vertebrate animals.**

Nothing to Report

- **Significant changes in use of biohazards and/or select agents**

Nothing to Report

5. **PRODUCTS:**

Publications, conference papers, and presentations

▪ Journal publications.

Unachukwu U, Chada K, D'Armiento J. High Mobility Group AT-Hook2 (HMGA2) Oncogenicity in Mesenchymal and Epithelial Neoplasia Int J Mol Sci. (2020) Apr 29;21(9). doi: 10.3390/ijms21093151. Review. PubMed PMID: 32365712.

Unachukwu, U.; Shiomi, T.; Goldklang, M.; Chada, K.; D'Armiento, J., Renal Neoplasms in Tuberous Sclerosis Mice are Neurocristopathies (2021) iScience, 24, 102684, doi:https://doi.org/10.1016/j.isci.2021. 102684.

- **Books or other non-periodical, one-time publications.**

Nothing to Report.

- **Other publications, conference papers, and presentations.**

Unachukwu, U., Shiomi, T., Goldklang, M., Damoci, C., Chada, K., and D'Armiento, J. The Neural Crest Origin of Tuberous Sclerosis American Thoracic Society International Meeting (2021)

Unachukwu, U. and D'Armiento, J. Defining the Pathogenic Role of Neural Crest Cells in Lymphangioleiomyomatosis: Mechanistic and Therapeutic Implications (2023)

- **Website(s) or other Internet site(s)**

Nothing to Report.

- **Technologies** **or** **techniques**

Nothing to Report

- **Inventions, patent applications, and/or licenses**

Nothing to Report.

- **Other Products**

Nothing to Report

6. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

- **What individuals have worked on the project?**

Name	Jeanine D'Armiento, MD, PhD
Project Role:	Principal Investigator
Researcher Identifier	
Contribution to Project:	1 person Month
Funding Support:	No Change

Name	Uchenna Unachukwu
Project Role:	Associate Research Scientist
Researcher Identifier	
Contribution to Project:	6 person Months
Funding Support:	No Change

Name	Tina Zelonina
Project Role:	Technician
Researcher Identifier	
Contribution to Project:	5 person months

Funding Support:	No Change
------------------	-----------

- **Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

Nothing to Report

- **What other organizations were involved as partners?**

Nothing to Report

7. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS:

Not applicable


QUAD CHARTS:

Not applicable

8. APPENDICES:

Article

Renal neoplasms in tuberous sclerosis mice are neurocristopathies



Uchenna
Unachukwu,
Takayuki Shiomi,
Monica
Goldklang, Kiran
Chada, Jeanine
D'Armiento

jmd12@cumc.columbia.edu

Highlights

Renal and hepatic tumors in $Tsc2^{+/-}$ mice comprise of neural crest cells (NCCs)

NCC proliferation increased with $Tsc2^{+/-}$ mice tumor volume and multiplicity

Multipotent $Tsc2^{+/-}$ NCCs induce tumors in ectodermally derived and non-neural tissues

Pharmacologically targeting NCCs offers an alternate treatment for tuberous sclerosis

Unachukwu et al., iScience 24,
102684
July 23, 2021 © 2021 The
Authors.
<https://doi.org/10.1016/j.isci.2021.102684>

Article

Renal neoplasms in tuberous sclerosis mice are neurocristopathies

Uchenna Unachukwu,¹ Takayuki Shiomi,² Monica Goldklang,¹ Kiran Chada,³ and Jeanine D'Armiento^{1,4,*}

SUMMARY

Tuberous sclerosis (TS) is a rare disorder exhibiting multi-systemic benign neoplasms. We hypothesized the origin of TS neoplastic cells derived from the neural crest given the heterogeneous ecto-mesenchymal phenotype of the most common TS neoplasms. To test this hypothesis, we employed Cre-loxP lineage tracing of myelin protein zero (Mpz)-expressing neural crest cells (NCCs) in spontaneously developing renal tumors of *Tsc2*^{+/-}/*Mpz(Cre)*/*TdTomato*^{fl/fl} reporter mice. In these mice, ectopic renal tumor onset was detected at 4 months of age increasing in volume by 16 months of age with concomitant increase in the subpopulation of tdTomato⁺ NCCs from 0% to 6.45% of the total number of renal tumor cells. Our results suggest that *Tsc2*^{+/-} mouse renal tumors arise from domiciled proliferative progenitor cell populations of neural crest origin that co-opt tumorigenesis due to mutations in *Tsc2* loci. Targeting neural crest antigenic determinants will provide a potential alternative therapeutic approach for TS pathogenesis.

INTRODUCTION

Tuberous sclerosis (TS) is characterized by highly variable benign neoplasms and hamartomatous lesions in the brain, skin, heart, lungs, and kidneys (Dabora et al., 2001), seizures, and TS-associated neuropsychiatric disorders (de Vries et al., 2015). Heterozygous mutations of the tuberous sclerosis genes *TSC1* or more frequently *TSC2* have been causatively linked to the abnormal cytological proliferation characterizing tumors in patients with TS (Carsillo et al., 2000; Giannikou et al., 2016; Jones et al., 1999; Sato et al., 2002; Smolarek et al., 1998; Yu and Henske, 2010); however, not all tumors exhibit mutations in these genes (Sancak et al., 2005; Tyburczy et al., 2015). These *TSC1/2* mutations lead to hyperactivation of the mechanistic target of rapamycin (mTOR) pathway in a subset of the tumors (Clements et al., 2015; Goncharova et al., 2002), which have since informed the Food and Drug Administration-approved use of mTOR inhibitors for treatment of TS (Barrera et al., 2013; Bissler et al., 2008; Franz et al., 2013; McCormack et al., 2011). Although inhibition of the mTOR complexes 1/2 (mTORC1/2) exerts cytostatic effects on tumor cells, the treatment is transient and not curative (Barrera et al., 2013; Davies et al., 2011; Yao et al., 2014), causing recurrence of tumors upon cessation of therapy (Bee et al., 2018; McCormack et al., 2011). This limitation in the therapeutic effects of mTOR pathway inhibitors could well be due to the fact that many patient tumors do not exhibit *TSC* mutations (Beauchamp et al., 1998; Niida et al., 1999, 2001) and express the tuber protein (Badri et al., 2013; Johnson et al., 2002). Given the debilitating phenotypes in multiple organs resulting in poor clinical outcomes, it is imperative we urgently resolve the source of pathogenic cells in TS. Not only will such knowledge foster the development of more effective treatment and prophylaxis for TS, providing relief to over 2 million sufferers worldwide (Kingswood et al., 2016), understanding the origin of TS lesions and tumors will clarify the sporadic and unpredictable nature of disease pathogenesis. Currently, the precise identification of the source of pathogenic cells in TS remains unclear (Henske et al., 2016; Henske and McCormack, 2012; Lam et al., 2018).

Histologically, TS neoplasms commonly comprise immature cells exhibiting either neuronal characteristic, as found in cortical tubers, subependymal giant cell astrocytomas, and retinal astrocytic hamartomas, and non-neuronal phenotypes found mostly outside of central nervous system (CNS) organs (Brigo et al., 2018; Delaney et al., 2014; Feliciano, 2020). While evidence supporting the postulate that CNS lesions originate due to mTOR-induced neural dysplasia, hyperexcitability, abnormal differentiation, and defective maturation of neural progenitor cells during embryonic development is quite compelling (Feliciano et al., 2012; Lin et al., 2016; Park et al., 2018), the ontogenetic mechanisms of non-CNS lesions of TS is

¹Center for LAM and Rare Lung Disease, Department of Anesthesiology, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA

²Department of Pathology, International University of Health and Welfare, School of Medicine, 4-3 Kouzunomori, Narita-shi, Chiba 286-8686, Japan

³Department of Biochemistry, Rutgers-Robert Wood Johnson Medical School, Rutgers University, 675 Hoes Lane, Piscataway, NJ 08854, USA

⁴Lead contact

*Correspondence: jmd12@cumc.columbia.edu
<https://doi.org/10.1016/j.isci.2021.102684>



not well understood. For instance, some research groups have recently made strides to identify the potential origin of the TS neoplastic cells outside the CNS albeit non-concordant findings, including the hypotheses that lymphangioleiomyomatosis (LAM), the main pulmonary manifestation of TS, is caused by cells of a pleural mesothelial origin (Clements et al., 2020) or uterine origin (Guo et al., 2020). Similarly, postulates of a neural crest origin for renal angiomyolipomas (AMLs), the most common cause of mortality in adult TS (Lam et al., 2018), and patients with LAM have been proposed by others. These investigators have observed that lesions in LAM and renal AMLs comprise heterogeneous cells including those that consistently express markers of smooth muscle cells (α -SMA, vimentin, and desmin), melanocytes (HMB45, MART-1), and adipocytes (AdPLA2) (Taveira-DaSilva and Moss, 2015), cell types that are phenotypically mesenchymal and in most cases foreign to their host tissue interstitium (Henske and McCormack, 2012). Coupled with the multi-organ occurrence of TS lesions (Delaney et al., 2014; Henske and McCormack, 2012), the pathogenesis of LAM and non-CNS lesions in TS seems reminiscent of developmental paradigms of neural crest lineages that give rise to portions of the embryonic mesenchyme either as trunk neural crest cells (TNCCs), cranial neural crest cells (CNCC), and cardiac or vagal neural crest cells (NCCs) (Baggiolini et al., 2015). These neural crest subtypes are postulated to determine TS disease heterogeneity (Delaney et al., 2014; Henske and McCormack, 2012), and the timing of *Tsc1/2* mutations in these cells during embryogenesis is predicted to govern the severity of the TS and LAM phenotype (Delaney et al., 2014). However, no experimental data exist to support the hypothesis which remains to be directly and comprehensively investigated (Delaney et al., 2014). Cumulatively, these studies do suggest that TS neoplasms have an embryogenic origin.

Given the relatively high frequency of renal lesions in TS, TS-associated lymphangioleiomyomatosis (TS-LAM), and sporadic LAM (S-LAM) (Dixon et al., 2011; Rakowski et al., 2006; Siroky et al., 2011), we employed a tuberous sclerosis *Tsc2*^{+/-} reporter mouse model that spontaneously develops renal cystadenomas (Onda et al., 1999) to test the hypothesis that mouse renal neoplasms are neurocristopathies, pathologies borne of a neural crest lineage. The expression of the tdTomato (*TdT*) reporter gene in these mice is governed by a Cre-recombinase-driven event under the control of the myelin protein zero (*Mpz*) promoter, a neural crest lineage marker (Yamauchi et al., 1999). This enables tissues derived from the neural crest to be detected in these mice and pathogenic cells of neural crest lineage to be determined and tracked in growing tumors of the tuberous sclerosis mice and in postmortem biochemical analyses. *Mpz* expression has previously been associated with multipotent post-migratory differentiating neural crest progenitors that exhibit fate restrictions including smooth muscle-like cells, glia, and neurons dependent on the cellular context and instructive environmental cues (Dupin and Coelho-Aguiar, 2013; Hagedorn et al., 1999). HMB45-positive angiomyolipoma and cystic single cells have also been identified in otherwise normal renal parenchyma (Siroky et al., 2011) reminiscent of migratory pathogenic neural crest-derived cells that defines our hypothesis (Pacheco-Rodriguez and Moss, 2010). The slow development of these tumors in the heterozygote *Tsc2* mice (Kwiatkowski, 2010; Onda et al., 1999) mimics the gradual benign growth pattern of TS hamartomas in most patients making this mouse model a suitable translational animal model for this study.

Using a non-invasive imaging strategy comprising epifluorescent IVIS spectral imaging and small animal ultrasound, we report the earliest detection of ectopic renal neoplasms in these tuberous sclerosis mice at 4 months of age. We resolved that a small population of primitive neural crest precursors, whose number increases with increasing tumor volume and maturity, populates renal tumors in the tuberous sclerosis mice and could source renal tumor ontogenesis in TS.

RESULTS

Generation of the tuberous sclerosis reporter mouse model

To determine whether TS tumor cells originate from a neural crest lineage, we generated a recapitulative mouse model by crossing floxed B6.Cg-Gt(ROSA)26Sor^{tm9(CAG-tdTomato)Hze/J} reporter mice with transgenic B6N.FVB-Tg(Mpz-Cre)26Mes/J mice. Using genotyping studies, we next selected *Mpz*(Cre)/*TdT*^{fl/fl} reporter mice progeny expressing TdT driven by the myelin protein zero promoter (*Mpz*) (Yamauchi et al., 1999). Upon breeding these mice with the *Tsc2*^{+/-} tuberous sclerosis mice (Onda et al., 1999) and F1 hybrid crosses of resulting *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/+} progeny, experimental mice denoting genotypes *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl}, *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{+/+}, *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl}, and wild-type control *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{+/+} mice were aged for 16 months to allow for tumor development. A schematic of genetic crosses involved in the development of this mouse model is displayed in Figure 1A. These crossings generate an animal model that allows for systemic epifluorescent detection of neural crest lineage cells in developing TS




Figure 1. Generation of tuberous sclerosis reporter mouse model

(A) Schematic of genetic crosses to generate *Tsc2*^{+/-} reporter mouse models shows floxed *R26Sor*^{tm9(CAG-tdTomato)/Hze} mice (female, N = 10 animals) were crossed with Tg(Mpz-Cre)26Mes mice (male, N = 10 animals) expressing Cre recombinase under the control of myelin protein zero (Mpz) promoter. Mice with *Mpz(Cre)*^{tm1.1JDar} mouse progeny (male/female, N = 8 animals) were then mated with *Tsc2*^{+/-} mice (male/female, N = 10 animals) to source *Tsc2*^{+/-}/*Mpz(Cre)*/TdTomato^{fl/fl} tuberous sclerosis reporter mouse models (shown in red) (male/female, N = 24 animals) that spontaneously develop renal tumors driven by neural crest cells labeled with tdTomato.

(B) IVIS spectral images of abdominopelvic cavities of 1.3-yr-old *Tsc2*^{+/-}/*Mpz*(Cre)/*TdTomato*^{fl/fl} tuberous sclerosis mouse model compared to age-matched *Tsc2*^{+/-}/*Mpz*(Cre)*TdTomato*^{+/-} and *Tsc2*^{+/-}/*Mpz*(Cre)*TdTomato*^{fl/fl} mice distinguishing epifluorescence of tdTomato-expressing regions.

(C) Average radiant efficiency was used to compare tdTomato epifluorescence in these mouse models by one-way analysis of variance (ANOVA) and post-hoc Dunnett's test ($p < 0.0001^{****}$). Small animal ultrasound scans of sagittal sections of normal kidney (NK) parenchyma in adult wild-type mice imaged on a viewing stage in supine position (D1) in comparison to renal sagittal sections in $Tsc2^{+/-}Mpz(Cre)TdT^{fl/fl}$ mice (D2) with labeled sites of tumors (T). BV denotes blood vessels. Rapid magnetic resonance images of kidneys (E) in $Tsc2^{+/-}Mpz(Cre)TdT^{fl/fl}$ mice identifying tumors (T) shown with arrows. See also [Figures S1A–S1C](#) comparing ultrasound and MRI images of tumorigenic hepatic tissues in $Tsc2^{+/-}Mpz(Cre)/TdT^{fl/fl}$ mice to normal liver tissue of $Tsc2^{+/-}Mpz(Cre)/TdT^{fl/fl}$ mice.

tumors by Cre-recombinase-mediated insertion of the *Mpz* promoter to drive tdTomato expression (Liu et al., 2015; Yamauchi et al., 1999). Tumor tracking in this *Tsc2*^{+/-} reporter mice was performed beginning at 2 months of age at biweekly intervals using sequential In Vivo Imaging System (IVIS) spectral imaging detecting tdTomato excitation/emission spectra at 570 nm/620 nm and small animal ultrasound. Small animal magnetic resonance imaging was used to confirm sites of tumor development prior to excision for subsequent analysis. Figure 1B displays results of IVIS spectral imaging of an array of 16-month-old littermate progeny of the selected genotypes used in this study showing tdTomato epifluorescence to be perceptibly brightest in the abdominal region of only the *Tsc2*^{+/-}/*Mpz*(Cre)/TdT^{fl/fl} mice. Spectral quantification of tdTomato epifluorescence revealed significantly higher average radiant efficiency measurements ($p < 0.0001^{***}$) in *Tsc2*^{+/-}/*Mpz*(Cre)/TdT^{fl/fl} mice compared to other mouse genotypes in two different sets of mice imaging studies (Figure 1C). TS tumorigenesis in this select mouse group was further verified by ultrasound imaging resolving regions representing multiple peripheral tumors in the kidneys of *Tsc2*^{+/-}/*Mpz*(Cre)/TdT^{fl/fl} mice (Figure D2) compared to tumor-less renal tissue in the *Tsc2*^{+/+}/*Mpz*(Cre)/TdT^{fl/fl} mice (Figure D1). High-resolution magnetic resonance imaging confirmed the presence of bilateral cortical tumor growth in both kidneys of the *Tsc2*^{+/-}/*Mpz*(Cre)/TdT^{fl/fl} mice (Figure 1E). *Tsc2*^{+/-}/*Mpz*(Cre)/TdT^{+/+} mice spontaneously developed renal tumors which could not be detected by tdTomato epifluorescence. Hepatic lesions were also detected in the 16-month-old *Tsc2*^{+/-}/*Mpz*(Cre)/TdT^{fl/fl} mice by ultrasound imaging (Figure S1B) compared to cross-sectional images of non-tumorigenic hepatic tissues recovered from *Tsc2*^{+/+}/*Mpz*(Cre)/TdT^{fl/fl} mice (Figure S1A). The presence of hepatic lesions in the *Tsc2*^{+/-}/*Mpz*(Cre)/TdT^{fl/fl} mice was further confirmed by high-resolution MRI (Figure S1C).

Renal tumorigenesis in *Tsc2*^{+/-} mice correlates with onset and proliferation of neural crest precursor populations

Prior to our study, the earliest reported detection of renal neoplasms in tuberous sclerosis *Tsc2*^{+/-} mouse models was at 6 months of age (Kobayashi et al., 1999; Kwiatkowski, 2010; Lam et al., 2018; Onda et al.,




Figure 2. Renal tumorigenesis in *Tsc2*^{+/-} mice correlates with onset and proliferation of neural crest precursor populations

(A–D) Earliest reported detection of ectopic renal tumors in the *Tsc2*^{+/-}*Mpz(Cre)**TdTomato*^{fl/fl} mice at 4 months of age (A), then pictured at 6 months (B), 12 months (C), and 16 months (D).

(E) Tumor volume increased from $4.68 \pm 1.5 \text{ mm}^3$ at 4 months of age (male/female, N = 5 animals) to $9.66 \pm 1.9 \text{ mm}^3$ at 6 months (male/female, N = 6 animals), to $56.8 \pm 16.0 \text{ mm}^3$ at 12 months (male/female, N = 5 animals), and then increasing by over 1,100% to $645 \pm 202 \text{ mm}^3$ by 16 months of age (male/female, N = 6 animals).

(F–H) (F) The average number of tumors per mice increased proportionally during the same period from 1.50 ± 0.3 (N = 5 animals; $p = 0.895$) in 4-month-old mice, to 4.80 ± 2.6 (N = 6 animals) in 6-month-old mice, and 7.50 ± 0.7 (N = 5 animals; $p = 0.068$) in 12-month-old mice, reaching statistical significance in 16-month-old mice (8.40 ± 3.4 ; $*p = 0.025$; N = 6 animals) compared to the 2-month-old mice. Representative images of hematoxylin/eosin (H/E)-stained immunohistochemical slides of renal tissue cross sections (4μM thickness) from 12-month-old *Tsc2*^{+/-}*Mpz(Cre)**TdTomato*^{fl/fl} mice (G) and *Tsc2*^{+/-}*Mpz(Cre)**TdTomato*^{fl/fl} mice (H).

(I) Renal tumors from 4- to 16-month-old *Tsc2*^{+/-}*Mpz(Cre)**TdTomato*^{fl/fl} mice were dissociated, gated for live/dead staining (Sytox Green⁽⁻⁾/DAPI⁽⁻⁾/DRAQ5⁽⁺⁾), and sorted for tdTomato expression in comparison with renal cortical cells obtained from age-matched *Tsc2*^{+/-}*Mpz(Cre)**TdTomato*^{fl/fl} mice.

1999), and earlier polycystic lesions occurring in the *Dermo1*^{Cre}*Tsc2*^{fl/fl} mice led to mouse lethality by 3 weeks of age (Ren et al., 2016). We report the earliest detection of ectopic fluid-filled renal cysts spontaneously developing in *Tsc2*^{+/-}*Mpz(Cre)**TdTomato*^{fl/fl} by 4 months of age (Figure 2A). These tumors were detectable by both IVIS spectral imaging and ultrasound. By 6 months of age, multiple solid tumors and/or cysts containing denser fluid can be observed (Figure 2B), which increased in volume by 12 months (Figure 2C), and by 16 months, enlarged, dysmorphic, inflamed renal tissue coalescing with multiple cysts could be observed (Figure 2D). Individual renal tumor volumes varied widely within the same kidney and mice at all ages, doubling in the mean volume from $4.68 \pm 1.5 \text{ mm}^3$ at 4 months of age (N = 4 mice) to $9.66 \pm 1.9 \text{ mm}^3$ at 6 months (N = 5 mice), to $56.8 \pm 16.0 \text{ mm}^3$ at 12 months (N = 3 mice), and then increasing by over 1,100% to $645 \pm 202 \text{ mm}^3$ by 16 months of age (Figure 2E). The average number of renal tumors per mice increased from 1.50 ± 0.3 (N = 4 mice; $p = 0.895$) in 4-month-old mice, to 4.80 ± 2.6 (N = 5 mice; $p = 0.213$) in 6-month-old mice, and to 7.50 ± 0.7 (N = 3 mice; $p = 0.068$) in 12-month-old mice, reaching statistical significance in 16-month-old mice (8.40 ± 3.4 tumors; N = 5 mice; $*p = 0.025$) compared to the 2-month-old mice (Figure 2F).

Tsc2^{+/-} mice renal tumors and comparative renal cortical tissues were excised at 4, 6, 12, and 16 months. Representative images of hematoxylin/eosin (H/E)-stained immunohistochemical slides of renal tissue cross sections (4 μm thickness) from 12-month-old *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl} mice (Figure 2G) and *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl} mice (Figure 2H) are depicted. *Tsc2*^{+/-} reporter mice renal tissues and tumors were dissociated into single cell populations for flow cytometric sorting of tdTomato⁺ NCCs. Results indicate that the significant increase in renal tumor volume (Figure 2E) and number of tumors (Figure 2F) in *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl} mice over the 16-month-period correlated with a marked increase in the fraction of gated tdTomato⁺ cells from an average of 0.60% beginning at 6 months, to 10.6% at 12 months, and 7.8% of the total number of sorted cells at 16 months (Figure 2I) compared to sorted cell fractions from *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl} mice and *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{+/+} following gating protocols for live cells (DAPI⁽⁻⁾/Sytox Green⁽⁻⁾/DRAQ5⁽⁺⁾) and tdTomato⁽⁺⁾. Representative dot plots comparing gating results of flow cytometric separation of renal tissue and tumor cells between *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl} and *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl} obtained at 4 months (Figures 3A and 3B), 6 months (Figures 3C and 3D), 12 months (Figures 3E and 3F), and 16 months (Figures 3G and 3H), respectively, are also displayed. Single cell suspensions of CNCCs (Figure 3I) and TNCCs (Figure 3J) excised from 9.5dpc *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl} mice embryos were used as positive controls to comparatively assess the emergence of tdTomato⁺ NCCs in tuberous sclerosis *Tsc2*^{+/-} mice. The resolution of tdTomato⁺ cells in renal tumor cell dissociates indicates active *Mpz* promoter activity in cells of a neural crest lineage. This unique cell population likely results from migrants from the neural crest that retain their proliferative and stem cell character and differentiate into source pathogenic tumor cells of TS, as phenotypic manifestations of mono-allelic and biallelic mutations at the *Tsc2* gene locus. Although the fraction of these tdTomato-expressing cells in both the gated and whole-cell populations analyzed by flow cytometry is quite low, they are proportional in quantity to the NCC precursors recoverable from 9.5dpc embryonic cranial tissue and mesodermal somite used as our cranial and trunk NCC controls, respectively (Figures 3I and 3J).

Characterization of neural crest lineage cells in *Tsc2*^{+/-} mouse renal tumors

Immunohistochemical preparations of excised renal tumor slices (4 μm thickness) obtained from 6-month-old *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl} mice revealed red fluorescent punctate cell masses occurring singly or in small colonies in the renal tumor slices following fluorescence excitation using the Texas Red chromatic filter (Figures 4A and 4B). The proportion of red fluorescent cells in renal tumors increased with age where even more colonies can be seen in the 12-month-old *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl} mouse tumor slices (Figures 4C and 4D) and 16-month-old *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl} mouse tumor slices (Figures 4F–4H) compared to renal tissue wildtype at the *Tsc2* locus (Figure 4E). Double immunolabeling studies using the 16-month-old renal tumor slices reveal significant expression of neural crest marker CD57 (β-1,3-glucuronyltransferase (B3GAT1)) in select renal tumor cells by confocal microscopy, along with 4',6-diamidino-2-phenylindole (DAPI) nuclear staining and endogenous tdTomato expression reporting the tumor's neural crest phenotype (Figure 3H). These tdTomato⁺ cell masses were also observed in hepatic tumor slices obtained from *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl} mice (Figures S1D and S1E). The myelin protein zero (*Mpz*)-driven tdTomato expression of cells in renal and hepatic tumors of the *Tsc2*^{+/-} reporter mice is a direct demonstration of a neural crest lineage for these tumors. Although we have not yet successfully extracted sufficient reliable genomic and proteomic material from tdTomato⁺ flow-sorted cells for downstream applications in this pilot study, RT-qPCR analysis of excised whole renal tumors from *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl} mice compared to age-matched *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl} mice renal tissue exhibited significantly higher expression of select neural crest markers *Ap2α* ($p = 4.40 \times 10^{-3**}$) and *CD57* ($p = 0.05^*$) (Figure 5A) in renal tumors assessed including *Tsc2*-null and *Tsc2*-expressing mouse renal tumors. In aggregate, *Tsc2*^{+/-} mice renal tumors assessed in this study did not exhibit significantly different *Tsc2* gene expression compared to renal cortical tissues in normal mice ($p = 0.0824$) (Figure 5B) in concordance with findings from our previous studies using this mouse model (D'Armiento et al., 2016).

DISCUSSION

The present study demonstrates through lineage tracing that renal angiomyolipomas and hepatic tumors in *Tsc2*^{+/-} reporter mouse models harbor NCCs. The occurrence of this population of NCCs was confirmed using fluorescent and confocal microscopy, flow cytometric analyses, and immunohistochemistry, substantiating the lineage tracing results. The lineage tracing studies utilizing the myelin protein zero (*Mpz*) promoter, therefore, are representative of expression of the ectodermal neural crest. The immunologic expression of canonical neural crest marker *CD57* in tdTomato-positive renal tumor cells (Figure 3H) further confirms their neural crest cellular identity, as well as the differential expression of multiple neural crest




Figure 3. Flow cytometric analysis of tdTomato-positive neural crest precursors in *Tsc2*^{+/-} reporter mice renal tumors

Representative flow cytometric data comparing single-cell events obtained between renal cortical tissue of *Tsc2*^{+/-} *Mpz(Cre)TdTomato*^{fl/fl} mice and *Tsc2*^{+/-} *Mpz(Cre)TdTomato*^{fl/fl} reporter mice at 4 months (A and B), 6 months (C and D), 12 months (E and F), and 16 months (G and H) are displayed, respectively. Single-cell suspensions of cranial neural crest cells (CNCCs) (I) and trunk neural crest cells (TNCCs) (J) excised from the 9.5dpc *Tsc2*^{+/-} *Mpz(Cre)TdTomato*^{fl/fl} mice embryos were used as positive controls to assess the emergence of tdTomato⁺ neural crest cells in tuberous sclerosis mice. Flow cytometric data shown is one representative experiment of doublet studies performed at different times using N = 2-3 mice/genotype/age group/experiment. Acquisition and analyses of flow cytometric data was performed on a Bio-Rad S3e cell sorter and analyzed using FlowJo 10.7.1/FCS Express 7 Plus software. All statistics were performed using a one-way ANOVA with post-hoc Dunnett test for multiple comparisons.

markers in diseased mouse renal tumors compared to healthy kidney tissues. The multipotency demonstrated by the expression pattern suggests that the tumor cell subpopulations are migrant neural crest progenitor relics of neurocristogenesis that have co-opted tumorigenesis in their various domiciled organs. Interestingly, the NCCs increased in number as the mice aged and the tumors increased in size. The described findings potentially allow for the development of efficacious targeted therapy for this untreated rare disease.

It is well established that neural crest progenitor cells are destined to delaminate from the neural tube, undergo epithelial-mesenchymal transitions (EMT), and invade multiple organs to give rise to CNCCs and trunk and vagal NCCs (Minarcik and Golden, 2003; Osumi-Yamashita et al., 1994; Serbedzija et al., 1992). NCCs are variably lineage restrictive in their multipotency, maintaining their ability to differentiate into few or many different cell types (Achilleos and Trainor, 2012; Baroffio et al., 1991; Calloni et al., 2009; Krispin et al., 2010; Motohashi et al., 2011), while retaining their multipotent self-renewal capacity even into adulthood in mammals (Bhatt et al., 2013). Interestingly, these cytogenetic activities mimic routine tumor cell physiology with ample evidence existing to demonstrate that cancer cells co-opt many of the genetic and molecular mechanisms used by developing NCCs including EMT, proliferation, migration, and differentiation (Maguire et al., 2015). Furthermore, the fate of these migratory and post-migratory NCCs is not completely determined, even after domiciliation in target organs, because they continue to generate multiple tissue derivatives (Maguire et al., 2015). The predilection of renal neoplasms in the *Tsc2*^{+/-} mice and in most patients with TS could well be due to these embryogenetic lineage restrictions in the tumorigenic *Tsc2*^{+/-} NCC subpopulations. Additionally, renal organs could also possess the most conducive microenvironment to co-opting tumorigenesis in these cells due to the presence of activating factors such as hormone stimulation (Yu et al., 2009).

The findings from the foregoing studies present a number of interesting possibilities. Given the embryonic nature of NCCs, it can be assumed that tumors in the tuberous sclerosis *Tsc2*^{+/-} mouse model harbor NCCs possessing mono-allelic germline mutations at the *Tsc2* gene loci. As haploinsufficient TS mutations have been shown to suffice for TS and LAM pathogenicity similar to *Tsc2*^{-/-} neoplastic cells (D'Armiento et al., 2016; Julian et al., 2017; Martin et al., 2017; Peri et al., 2017; Tam et al., 2019), multipotent *Tsc2*^{+/-} NCCs could induce tumor development in both ectodermally-derived neural and non-neural tissues (Feliciano, 2020; Ferrans et al., 2000) located in multiple organs that are ontogenetic destinations for neural crest progenitor cells (Delaney et al., 2014). Supporting this postulate is the recent delineation of catabolic signaling potentially inducing mesenchymal lineage specificity in human pluripotent stem cell-derived NCCs upon complete ablation of *Tsc2* expression (Delaney et al., 2020). Similarly, *Tsc1*^{-/-} NCCs were observed to drive the development of sclerotic craniofacial bone lesions in a floxed *Tsc1*^{-/-} *Mpz* mouse model (Fang et al., 2015). Furthermore, concomitant increase in tumor volume and number with increases in the proportion of tdTomato⁺ NCCs identified in this study could indicate that more *Tsc2*^{+/-} NCCs initiate increased interstitial paracrine signaling that thus co-opt a greater number of host cells expanding proliferation and secretion of cystic volume. More tdTomato⁺ NCCs engaging in self-renewal proliferative processes can account for large numbers of tumors in the same or varied organs which altogether index more aggressive tumorigenic phenotypes.

Mutations in the *Tsc1* and predominantly the *Tsc2* gene loci give rise to constitutive mTOR kinase activity and unregulated cell growth and metabolism causing TS tumors (El-Hashemite et al., 2003; Giannikou et al., 2016; Inoki et al., 2003; Kenerson et al., 2007). However, in studies conducted by our group and others (Hartman et al., 2009; Higa et al., 2009; Lee et al., 2010; Li et al., 2014), several mTOR-independent pathogenic mechanisms for TS have been demonstrated in diseased tissues haploinsufficient at the *Tsc2* locus. Such exemplary mTOR-independent signaling was observed in our studies demonstrating the requirement of the misexpression of DNA transcription factor High-Mobility Group (*Hmga2*) in mesenchymal and




Figure 4. Visualizing neural crest lineage cells in $Tsc2^{+/-}$ mouse renal tumors

(A–D) Representative tdTomato and merged tdTomato/DAPI images of immunohistochemical slices (4 μ m thickness) of renal tumors showing punctate singlets and colonies of tdTomato⁺ neural crest cell populations obtained in 6-month-old (A and B) and 12-month-old (C and D) $Tsc2^{+/-}$ Mpz(Cre)TdT^{fl/fl} mice viewed using an excitation filter of 540/45 nm in a confocal microscope.

(E–H) (E) Comparative image panel of renal tissue from wild-type 12-month-old mice. Double immunolabeling of renal tumor slices obtained from 16-month-old $Tsc2^{+/-}$ Mpz(Cre)TdT^{fl/fl} mice reveal tandem endogenous expression of Mpz-driven tdTomato red fluorescent protein (F), Alexa Fluor 488-labeled CD57 neural crest marker expression (G), and tdTomato/CD57/DAPI merged images (H) confirming neural crest identity of these cells. Confocal and fluorescence imaging was performed using N = 3 slides; 2 sections/slide to visualize each renal tumor/tissue. Scale bar represents 50 μ m. See also Figures S1D and S1E for fluorescent imaging of immunohistochemical slices of hepatic lesions of $Tsc2^{+/-}$ Mpz(Cre)/TdT^{fl/fl} mice showing punctate tdTomato⁺ NCCs.

epithelial tumors, and the concomitant expression of upstream and downstream targets of *Hmga2* such as insulin-like growth factor 2 mRNA-binding protein 2 (*Igf2bp2*), *let-7*, and *lin28* in $Tsc2^{+/-}$ mouse tumors (Berner et al., 1997; D’Armiento et al., 2007; D’Armiento et al., 2016; Hunter et al., 2002; Kazmierczak et al., 1996; Tallini et al., 2000). This implicates an active *Hmga2* pathway inducing tumorigenesis in these




Figure 5. Neural crest marker expression in *Tsc2*^{+/-} mouse renal tumors

(A) RNA extracts of *Tsc2*^{+/-}*Mpz(Cre)TdT^{fl/fl}* mice kidney parenchyma and *Tsc2*^{+/-}*Mpz(Cre)TdT^{fl/fl}* mice renal tumors from 16-month-old mice analyzed by RT-qPCR for neural crest marker expression depict significantly increased expression of transcription factor activating protein—*Tfp2a* ($p = 4.40 \times 10^{-3**}$) and *CD57* (β -1,3-glucuronyltransferase (B3GAT1)) ($p = 0.05^*$).

(B) There was no statistically significant difference in *Tsc2* gene expression state between wild-type kidney tissues and renal tumors in *Tsc2*^{+/-} mice ($p = 0.0824$). RT-qPCR experiments were performed using triplicate biological samples applied in PCR plates in quadruplicates.

study models. Given our findings and above that TS tumors are phenotypically mesenchymal and originate from the neural crest and the exclusive expression of *Hmga2* in embryonic undifferentiated mesenchyme (Chiappetta et al., 1996; Hock et al., 2006), *Hmga2* misexpression could potentially define the ability of *Tsc2*^{+/-} NCCs to form mesenchymal tumors. Furthermore, it is evident that the pathogenic cells of TS possess an enduring stemness characteristic. *HMGA2* as a stemness gene has been implicated in NCC fate specification (Macri et al., 2016) and self-renewal of NCC derivative neural stem cells (Nishino et al., 2008), regulating these developmental events in a manner similar to the gene's effect in propagating mammalian tumorigenesis (Macri et al., 2016; Nishino et al., 2008). NCC progenitors differentiate into ecto-mesenchymal tissue derivatives following EMT during embryogenesis (Duband, 2000; Duband et al., 1995). Given our prior determination of the necessity for expression of *Hmga2* for mesenchymal tumorigenesis in *Tsc2*^{+/-} mice, the gene's expression in 100% of human and mice TS tumors, and its influence in increasing the number of renal tumors (D'Armiento et al., 2016), *Hmga2* could be acting downstream of NCC delamination and *Tsc2* mutational events to determine the tumorigenic potential and destiny of migratory NCCs causative for TS neoplasms.

These studies provide evidence for a neural crest origin for tumorigenic cells in lesions from *Tsc2*^{+/-} mouse models and suggest that a treatment approach specifically targeting neural crest progenitor cells could potentially provide an alternative to mTOR inhibitors as treatment for TS. While mTOR inhibitors remain cytostatic to TS tumorigenic cells (Henske and McCormack, 2012), inhibitors to neural crest markers such as *AP2a* expressed in renal tumors examined in this study have the potential to inhibit DNA transcription and stymy tumor cell growth leading to an alternative or adjunctive therapeutic agent for TS.

Limitations of the study

Given the multi-systemic occurrence of neoplasms in patients with TS as well as in the *Tsc2*^{+/-} reporter mouse model, it would have been prudent to distinguish the genomic characteristic of individual tumors assessed from the same or different diseased mouse organ(s). However, the low proportion and viability of flow-sorted tdTomato+ renal tumor cells resolved in this study limited our ability to perform downstream biochemical analysis of excised tumors, necessitating our pooling of tumors for analysis. This was not an ideal methodology for comprehensive testing of our hypothesis that *Tsc2*^{+/-} mouse renal tumors were neurocristopathic because the characteristic phenotype of these different tumors is thus not known. Future

single-cell RNA sequencing studies of dissociated *Tsc2*^{+/-} mouse renal tumors will overcome this limitation. Additionally, the inability of the majority of *Tsc2*^{+/-} mice to spontaneously develop pulmonary tumors, as well as other regularly occurring tumors and phenotypes of patients with TS, limits its appropriateness as a model of TS and specifically LAM, central to our laboratory investigations. The short life span of the Mpz-driven tdTomato expression in renal tumors limits our ability for prolonged microscopic examination of renal tumor slices by confocal or fluorescence microscopy and employing anti-tdTomato antibodies did not diminish the quenching of the fluorescent signal.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
 - Lead contact
 - Materials availability
 - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Mouse genetic studies
- METHOD DETAILS
 - Tumor tracking protocols
 - Mouse renal tumor processing and flow cytometry
 - Neural crest cell culture
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.isci.2021.102684>.

ACKNOWLEDGMENTS

We thank Tina Zelonina for assistance in mouse breeding and genotyping, tumor excision, and volume measurements. We also thank Christopher Damoci for his technical expertise during small animal imaging and data analysis. This study was supported by grants from the Center for LAM and Rare Lung Diseases at Columbia University. J.D. is supported by NIH RO1-HL086936 and Congressionally Directed Medical Research Programs (CDMRP) grant (TS170057). U.U. is supported by Congressionally Directed Medical Research Programs (CDMRP) grant (TS170057). M.G. is supported by NIH KO8 (HL126071).

AUTHOR CONTRIBUTIONS

Conceptualization, U.U., T.S., K.C., and J.D.; methodology, U.U., T.S., M.G., and J.D.; investigation, U.U.; formal analysis, U.U.; resources, M.G. and J.D.; writing – original draft, U.U., T.S., and J.D.; writing – review & editing, U.U., M.G., K.C., and J.D.; visualization, U.U. and J.D.; supervision, K.C. and J.D.; funding acquisition, M.G. and J.D.

DECLARATION OF INTERESTS

The authors declare no competing interests.

INCLUSION AND DIVERSITY

We worked to ensure sex balance in the selection of non-human subjects. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in science. While citing references scientifically relevant for this work, we also actively worked to promote gender balance in our reference list. The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work.

Received: December 15, 2020

Revised: April 20, 2021

Accepted: May 31, 2021

Published: July 23, 2021

REFERENCES

- Achilleos, A., and Trainor, P.A. (2012). Neural crest stem cells: discovery, properties and potential for therapy. *Cell Res.* 22, 288–304.
- Au - Gonzalez Malagon, S.G., Au - Dobson, L., Au - Muñoz, A.M.L., Au - Dawson, M., Au - Barrell, W., Au - Marangos, P., Au - Krause, M., and Au - Liu, K.J. (2019). Dissection, culture and analysis of primary cranial neural crest cells from mouse for the study of neural crest cell delamination and migration. *JoVE*, e60051.
- Badri, K.R., Gao, L., Hyjek, E., Schuger, N., Schuger, L., Qin, W., Chekaluk, Y., Kwiatkowski, D.J., and Zhe, X. (2013). Exonic mutations of TSC2/TSC1 are common but not seen in all sporadic pulmonary lymphangioleiomyomatosis. *Am. J. Respir. Crit. Care Med.* 187, 663–665.
- Baggiolini, A., Varum, S., Mateos, J.M., Bettosini, D., John, N., Bonalli, M., Ziegler, U., Dimou, L., Clevers, H., Furrer, R., et al. (2015). Premigratory and migratory neural crest cells are multipotent in vivo. *Cell Stem Cell* 16, 314–322.
- Baroffio, A., Dupin, E., and Le Douarin, N.M. (1991). Common precursors for neural and mesectodermal derivatives in the cephalic neural crest. *Development* 112, 301.
- Barrera, P., Simons, S.O., Luijk, B., Wessels, M.J., and Heijdra, Y.F. (2013). Efficacy of sirolimus therapy for chyloous effusions in lymphangioleiomyomatosis. *Ann. Am. Thorac. Soc.* 10, 408–409.
- Beauchamp, R.L., Banwell, A., McNamara, P., Jacobsen, M., Higgins, E., Northrup, H., Short, P., Sims, K., Ozelius, L., and Ramesh, V. (1998). Exon scanning of the entire TSC2 gene for germline mutations in 40 unrelated patients with tuberous sclerosis. *Hum. Mutat.* 12, 408–416.
- Bee, J., Fuller, S., Miller, S., and Johnson, S.R. (2018). Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study. *Thorax* 73, 369–375.
- Berner, J.M., Meza-Zepeda, L.A., Kools, P.F., Forus, A., Schoenmakers, E.F., Van de Ven, W.J., Fodstad, O., and Myklebost, O. (1997). HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas. *Oncogene* 14, 2935–2941.
- Bhatt, S., Diaz, R., and Trainor, P.A. (2013). Signals and switches in Mammalian neural crest cell differentiation. *Cold Spring Harb. Perspect. Biol.* 5, a008326.
- Bissler, J.J., McCormack, F.X., Young, L.R., Elwing, J.M., Chuck, G., Leonard, J.M., Schmithorst, V.J., Laor, T., Brody, A.S., Bean, J., et al. (2008). Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. *N. Engl. J. Med.* 358, 140–151.
- Brigo, F., Lattanzi, S., Trinka, E., Nardone, R., Bragazzi, N.L., Ruggieri, M., Martini, M., and Walusinski, O. (2018). First descriptions of tuberous sclerosis by Désiré-Magloire Bourneville (1840–1909). *Neuropathology* 38, 577–582.
- Calloni, G.W., Le Douarin, N.M., and Dupin, E. (2009). High frequency of cephalic neural crest cells shows coexistence of neurogenic, melanogenic, and osteogenic differentiation capacities. *Proc. Natl. Acad. Sci. U S A* 106, 8947.
- Carsillo, T., Astrinidis, A., and Henske, E.P. (2000). Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. *Proc. Natl. Acad. Sci. U S A* 97, 6085–6090.
- Chiappetta, G., Avantaggiato, V., Visconti, R., Fedele, M., Battista, S., and Trapasso, F. (1996). High level expression of the HMG1 (Y) gene during embryonic development. *Oncogene* 13, 2439–2446.
- Clements, D., Dongre, A., Krymskaya, V.P., and Johnson, S.R. (2015). Wild type mesenchymal cells contribute to the lung pathology of lymphangioleiomyomatosis. *PLoS One* 10, e0126025.
- Clements, D., Miller, S., and Johnson, S.R. (2020). Pulmonary Lymphangioleiomyomatosis originates in the pleural mesothelial cell population. *Med. Hypotheses* 141, 109703.
- D'Armiento, J., Imai, K., Schiltz, J., Kolesnekova, N., Sternberg, D., Benson, K., Pardo, A., Selman, M., Smolarek, T., Vundavalli, M., et al. (2007). Identification of the benign mesenchymal tumor gene HMG2 in lymphangiomyomatosis. *Cancer Res.* 67, 1902–1909.
- D'Armiento, J., Shiomi, T., Marks, S., Geraghty, P., Sankarasharma, D., and Chada, K. (2016). Mesenchymal tumorigenesis driven by TSC2 haploinsufficiency requires HMG2 and is independent of mTOR pathway activation. *Cancer Res.* 76, 844–854.
- Dabora, S.L., Jozwiak, S., Franz, D.N., Roberts, P.S., Nieto, A., Chung, J., Choy, Y.S., Reeve, M.P., Thiele, E., Egelhoff, J.C., et al. (2001). Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. *Am. J. Hum. Genet.* 68, 64–80.
- Davies, D.M., de Vries, P.J., Johnson, S.R., McCartney, D.L., Cox, J.A., Serra, A.L., Watson, P.C., Howe, C.J., Doyle, T., Pointon, K., et al. (2011). Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. *Clin. Cancer Res.* 17, 4071–4081.
- de Vries, P.J., Whittemore, V.H., Leclézio, L., Byars, A.W., Dunn, D., Ess, K.C., Hook, D., King, B.H., Sahin, M., and Jansen, A. (2015). Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. *Pediatr. Neurol.* 52, 25–35.
- Delaney, S.P., Julian, L.M., Pietrobon, A., Yockell-Lelièvre, J., Doré, C., Wang, T.T., Doyon, V.C., Raymond, A., Patten, D.A., Kristof, A.S., et al. (2020). Human pluripotent stem cell modeling of tuberous sclerosis complex reveals lineage-specific therapeutic vulnerabilities. *bioRxiv*, 683359.
- Delaney, S.P., Julian, L.M., and Stanford, W.L. (2014). The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis. *Front. Cell Dev. Biol.* 2, 69.
- Dixon, B.P., Hulbert, J.C., and Bissler, J.J. (2011). Tuberous sclerosis complex renal disease. *Nephron Exp. Nephrol.* 118, e15–e20.
- Duband, J.L. (2000–2013). Neural crest delamination and migration: integrating regulations of cell interactions, locomotion, survival and fate. In *Madame Curie Bioscience Database (Landes Bioscience)*, pp. 1–42.
- Duband, J.L., Monier, F., Delannet, M., and Newgreen, D. (1995). Epithelium-mesenchyme transition during neural crest development. *Acta Anat. (Basel)* 154, 63–78.
- Dupin, E., and Coelho-Aguiar, J.M. (2013). Isolation and differentiation properties of neural crest stem cells. *Cytometry. A* 83, 38–47.
- El-Hashemite, N., Zhang, H., Henske, E.P., and Kwiatkowski, D.J. (2003). Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. *Lancet* 361, 1348–1349.
- Fang, F., Sun, S., Wang, L., Guan, J.L., Giovannini, M., Zhu, Y., and Liu, F. (2015). Neural crest-specific TSC1 deletion in mice leads to sclerotic craniofacial bone lesion. *J. Bone Miner. Res.* 30, 1195–1205.
- Faustino-Rocha, A., Oliveira, P.A., Pinho-Oliveira, J., Teixeira-Guedes, C., Soares-Maia, R., da Costa, R.G., Colaço, B., Pires, M.J., Colaço, J., Ferreira, R., et al. (2013). Estimation of rat mammary tumor volume using caliper and ultrasonography measurements. *Lab. Anim.* 42, 217–224.
- Feliciano, D.M. (2020). The neurodevelopmental pathogenesis of tuberous sclerosis complex (TSC). *Front. Neuroanat.* 14, 39.
- Feliciano, D.M., Quon, J.L., Su, T., Taylor, M.M., and Bordey, A. (2012). Postnatal neurogenesis generates heterotopias, olfactory micronodules and cortical infiltration following single-cell Tsc1 deletion. *Hum. Mol. Genet.* 21, 799–810.
- Ferrans, V.J., Yu, Z.X., Nelson, W.K., Valencia, J.C., Tatsuguchi, A., Avila, N.A., Riemenschn, W., Matsui, K., Travis, W.D., and Moss, J. (2000). Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. *J. Nippon Med. Sch.* 67, 311–329.
- Festing, M.F. (2006). Design and statistical methods in studies using animal models of development. *ILAR J.* 47, 5–14.
- Festing, M.F., and Altman, D.G. (2002). Guidelines for the design and statistical analysis of experiments using laboratory animals. *ILAR J.* 43, 244–258.
- Franz, D.N., Belousova, E., Sparagana, S., Bebin, E.M., Frost, M., Kuperman, R., Witt, O., Kohrman, M.H., Flamini, J.R., Wu, J.Y., et al. (2013). Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet* 381, 125–132.

- Giannikou, K., Malinowska, I.A., Pugh, T.J., Yan, R., Tseng, Y.Y., Oh, C., Kim, J., Tyburczy, M.E., Chekaluk, Y., Liu, Y., et al. (2016). Whole exome sequencing identifies TSC1/TSC2 biallelic loss as the primary and sufficient driver event for renal angiomyolipoma development. *PLoS Genet.* 12, e1006242.
- Goncharova, E.A., Goncharov, D.A., Eszterhas, A., Hunter, D.S., Glassberg, M.K., Yeung, R.S., Walker, C.L., Noonan, D., Kwiatkowski, D.J., Chou, M.M., et al. (2002). Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). *J. Biol. Chem.* 277, 30958–30967.
- Guo, M., Yu, J.J., Perl, A.K., Wikenheiser-Brokamp, K.A., Riccetti, M., Zhang, E.Y., Sudha, P., Adam, M., Potter, A., Kopras, E.J., et al. (2020). Single-cell transcriptomic analysis identifies a unique pulmonary lymphangioleiomyomatosis cell. *Am. J. Respir. Crit. Care Med.* 202, 1373–1387.
- Hagedorn, L., Suter, U., and Sommer, L. (1999). PO and PMP22 mark a multipotent neural crest-derived cell type that displays community effects in response to TGF-beta family factors. *Development* 126, 3781–3794.
- Hartman, T.R., Liu, D., Zilfou, J.T., Robb, V., Morrison, T., Watnick, T., and Henske, E.P. (2009). The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway. *Hum. Mol. Genet.* 18, 151–163.
- Henske, E.P., Jozwiak, S., Kingswood, J.C., Sampson, J.R., and Thiele, E.A. (2016). Tuberous sclerosis complex. *Nat. Rev. Dis. Primers* 2, 16035.
- Henske, E.P., and McCormack, F.X. (2012). Lymphangioleiomyomatosis - a wolf in sheep's clothing. *J. Clin. Invest.* 122, 3807–3816.
- Higa, F., Uchiyama, T., Haranaga, S., Yara, S., Tateyama, M., Oshiro, Y., Shiraiishi, M., Kumasaka, T., Seyama, K., and Fujita, J. (2009). Malignant epithelioid angiomyolipoma in the kidney and liver of a patient with pulmonary lymphangioleiomyomatosis: lack of response to sirolimus. *Intern. Med.* 48, 1821–1825.
- Hock, R., Witte, F., Brocher, J., Schutz, M., and Scheer, U. (2006). Expression of HMGA2 variants during oogenesis and early embryogenesis of *Xenopus laevis*. *Eur. J. Cell Biol.* 85, 519–528.
- Hunter, D.S., Klotzbucher, M., Kugoh, H., Cai, S.L., Mullen, J.P., Manfioletti, G., Fuhrman, U., and Walker, C.L. (2002). Aberrant expression of HMGA2 in uterine leiomyoma associated with loss of TSC2 tumor suppressor gene function. *Cancer Res.* 62, 3766–3772.
- Inoki, K., Li, Y., Xu, T., and Guan, K.L. (2003). Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. *Genes Dev.* 17, 1829–1834.
- Johnson, S.R., Clelland, C.A., Ronan, J., Tattersfield, A.E., and Knox, A.J. (2002). The TSC-2 product tuberin is expressed in lymphangioleiomyomatosis and angiomyolipoma. *Histopathology* 40, 458–463.
- Jones, A.C., Shyamsundar, M.M., Thomas, M.W., Maynard, J., Idziaszczyk, S., Tomkins, S., Sampson, J.R., and Cheadle, J.P. (1999). Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. *Am. J. Hum. Genet.* 64, 1305–1315.
- Julian, L.M., Delaney, S.P., Wang, Y., Goldberg, A.A., Doré, C., Yockell-Lelièvre, J., Tam, R.Y., Giannikou, K., McMurray, F., Shoichet, M.S., et al. (2017). Human pluripotent stem cell-derived TSC2-haploinsufficient smooth muscle cells recapitulate features of lymphangioleiomyomatosis. *Cancer Res.* 77, 5491–5502.
- Kaku, M., Komatsu, Y., Mochida, Y., Yamauchi, M., Mishina, Y., and Ko, C.-C. (2012). Identification and characterization of neural crest-derived cells in adult periodontal ligament of mice. *Arch. Oral Biol.* 57, 1668–1675.
- Kazmierczak, B., Rosigkeit, J., Wanschura, S., Meyer-Bolte, K., Van de Ven, W.J., Kayser, K., Krieghoff, B., Kastendiek, H., Bartnitzke, S., and Bullerdiek, J. (1996). HMGI-C rearrangements as the molecular basis for the majority of pulmonary chondroid hamartomas: a survey of 30 tumors. *Oncogene* 12, 515–521.
- Kenerson, H., Folpe, A.L., Takayama, T.K., and Yeung, R.S. (2007). Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. *Hum. Pathol.* 38, 1361–1371.
- Kingswood, C., Bolton, P., Crawford, P., Harland, C., Johnson, S.R., Sampson, J.R., Shepherd, C., Spink, J., Demuth, D., Lucchese, L., et al. (2016). The clinical profile of tuberous sclerosis complex (TSC) in the United Kingdom: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). *Eur. J. Paediatr. Neurol.* 20, 296–308.
- Kobayashi, T., Minowa, O., Kuno, J., Mitani, H., Hino, O., and Noda, T. (1999). Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. *Cancer Res.* 59, 1206–1211.
- Krispin, S., Nitzan, E., Kassem, Y., and Kalcheim, C. (2010). Evidence for a dynamic spatiotemporal fate map and early fate restrictions of premigratory avian neural crest. *Development* 137, 585.
- Kwiatkowski, D.J. (2010). Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC). *Lymphat Res. Biol.* 8, 51–57.
- Lam, H.C., Siroky, B.J., and Henske, E.P. (2018). Renal disease in tuberous sclerosis complex: pathogenesis and therapy. *Nat. Rev. Nephrol.* 14, 704–716.
- Lee, P.S., Tsang, S.W., Moses, M.A., Traves-Gibson, Z., Hsiao, L.L., Jensen, R., Squillace, R., and Kwiatkowski, D.J. (2010). Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. *Am. J. Respir. Cell Mol. Biol.* 42, 227–234.
- Li, C., Zhang, E., Sun, Y., Lee, P.S., Zhan, Y., Guo, Y., Osorio, J.C., Rosas, I.O., Xu, K.F., Kwiatkowski, D.J., et al. (2014). Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis. *PLoS One* 9, e104809.
- Lin, T.V., Hsieh, L., Kimura, T., Malone, T.J., and Bordey, A. (2016). Normalizing translation through 4E-BP prevents mTOR-driven cortical mislaminarization and ameliorates aberrant neuron integration. *Proc. Natl. Acad. Sci. U S A* 113, 11330.
- Liu, Z., Jin, Y.Q., Chen, L., Wang, Y., Yang, X., Cheng, J., Wu, W., Qi, Z., and Shen, Z. (2015). Specific marker expression and cell state of Schwann cells during culture in vitro. *PLoS One* 10, e0123278.
- Macri, S., Simula, L., Pellarin, I., Pegoraro, S., Onorati, M., Sgarra, R., Manfioletti, G., and Vignali, R. (2016). Hmga2 is required for neural crest cell specification in *Xenopus laevis*. *Dev. Biol.* 411, 25–37.
- Maguire, L.H., Thomas, A.R., and Goldstein, A.M. (2015). Tumors of the neural crest: common themes in development and cancer. *Dev. Dyn.* 244, 311–322.
- Martin, K.R., Zhou, W., Bowman, M.J., Shih, J., Au, K.S., Dittenhafer-Reed, K.E., Sisson, K.A., Koeman, J., Weisenberger, D.J., Cottingham, S.L., et al. (2017). The genomic landscape of tuberous sclerosis complex. *Nat. Commun.* 8, 15816.
- McCormack, F.X., Inoue, Y., Moss, J., Singer, L.G., Strange, C., Nakata, K., Barker, A.F., Chapman, J.T., Brantly, M.L., Stocks, J.M., et al. (2011). Efficacy and safety of sirolimus in lymphangioleiomyomatosis. *New Engl. J. Med.* 364, 1595–1606.
- Minarcik, J.C., and Golden, J.A. (2003). AP-2 and HNK-1 define distinct populations of cranial neural crest cells. *Orthod. Craniofac. Res.* 6, 210–219.
- Motohashi, T., Yamanaka, K., Chiba, K., Miyajima, K., Aoki, H., Hirobe, T., and Kunisada, T. (2011). Neural crest cells retain their capability for multipotential differentiation even after lineage-restricted stages. *Dev. Dyn.* 240, 1681–1693.
- Neelisetty, S., Alford, C., Reynolds, K., Woodbury, L., Nlandu-Khodo, S., Yang, H., Fogo, A.B., Hao, C.M., Harris, R.C., Zent, R., et al. (2015). Renal fibrosis is not reduced by blocking transforming growth factor-β signaling in matrix-producing interstitial cells. *Kidney Int.* 88, 503–514.
- Niida, Y., Lawrence-Smith, N., Banwell, A., Hammer, E., Lewis, J., Beauchamp, R.L., Sims, K., Ramesh, V., and Ozelius, L. (1999). Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis. *Hum. Mutat.* 14, 412–422.
- Niida, Y., Stemmer-Rachamimov, A.O., Logrip, M., Tapon, D., Perez, R., Kwiatkowski, D.J., Sims, K., MacCollin, M., Louis, D.N., and Ramesh, V. (2001). Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. *Am. J. Hum. Genet.* 69, 493–503.
- Nishino, J., Kim, I., Chada, K., and Morrison, S.J. (2008). Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing

p16Ink4a and p19Arf Expression. *Cell* 135, 227–239.

Onda, H., Lueck, A., Marks, P.W., Warren, H.B., and Kwiatkowski, D.J. (1999). Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. *J. Clin. Invest.* 104, 687–695.

Osumi-Yamashita, N., Ninomiya, Y., Doi, H., and Eto, K. (1994). The contribution of both forebrain and midbrain crest cells to the mesenchyme in the frontonasal mass of mouse embryos. *Dev. Biol.* 164, 409–419.

Pacheco-Rodriguez, G., and Moss, J. (2010). The role of chemokines in migration of metastatic-like lymphangioleiomyomatosis cells. *Crit. Rev. Immunol.* 30, 387–394.

Park, S.M., Lim, J.S., Ramakrishna, S., Kim, S.H., Kim, W.K., Lee, J., Kang, H.C., Reiter, J.F., Kim, D.S., Kim, H.H., et al. (2018). Brain somatic mutations in MTOR disrupt neuronal ciliogenesis, leading to focal cortical dyslamination. *Neuron* 99, 83–97.e7.

Peri, S., Caretti, E., Tricarico, R., Devarajan, K., Cheung, M., Sementino, E., Menges, C.W., Nicolas, E., Vanderveer, L.A., Howard, S., et al. (2017). Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. *Oncotarget* 8, 17628–17642.

Pfaltzgraff, E.R., Mundell, N.A., and Labosky, P.A. (2012). Isolation and culture of neural crest cells from embryonic murine neural tube. *J. Vis. Exp.* e4134.

Qin, W., Bajaj, V., Malinowska, I., Lu, X., MacConaill, L., Wu, C.L., and Kwiatkowski, D.J. (2011). Angiomyolipoma have common mutations in TSC2 but no other common genetic events. *PLoS One* 6, e24919.

Rakowski, S.K., Winterkorn, E.B., Paul, E., Steele, D.J., Halpern, E.F., and Thiele, E.A. (2006). Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. *Kidney Int.* 70, 1777–1782.

Ren, S., Luo, Y., Chen, H., Warburton, D., Lam, H.C., Wang, L.L., Chen, P., Henske, E.P., and Shi, W. (2016). Inactivation of Tsc2 in mesoderm-derived cells causes polycystic kidney lesions and impairs lung alveolarization. *Am. J. Pathol.* 186, 3261–3272.

Sancak, O., Nellist, M., Goedbloed, M., Elfferich, P., Wouters, C., Maat-Kievit, A., Zonnenberg, B., Verhoef, S., Halley, D., and van den Ouweland, A. (2005). Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype–phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. *Eur. J. Hum. Genet.* 13, 731–741.

Sápi, J., Kovács, L., Drexler, D.A., Kocsis, P., Gajári, D., and Sápi, Z. (2015). Tumor volume estimation and quasi-continuous administration for most effective bevacizumab therapy. *PLoS One* 10, e0142190.

Sato, T., Seyama, K., Fujii, H., Maruyama, H., Setoguchi, Y., Iwakami, S., Fukuchi, Y., and Hino, O. (2002). Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. *J. Hum. Genet.* 47, 20–28.

Serbedzija, G.N., Bronner-Fraser, M., and Fraser, S.E. (1992). Vital dye analysis of cranial neural crest cell migration in the mouse embryo. *Development* 116, 297.

Siroky, B.J., Yin, H., and Bissler, J.J. (2011). Clinical and molecular insights into tuberous sclerosis complex renal disease. *Pediatr. Nephrol.* 26, 839–852.

Smolarek, T.A., Wessner, L.L., McCormack, F.X., Mylet, J.C., Menon, A.G., and Henske, E.P. (1998). Evidence that lymphangioleiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangioleiomyomatosis. *Am. J. Hum. Genet.* 62, 810–815.

Sowa, Y., Imura, T., Numajiri, T., Takeda, K., Mabuchi, Y., Matsuzaki, Y., and Nishino, K. (2013). Adipose stromal cells contain phenotypically distinct adipogenic progenitors derived from neural crest. *PLoS One* 8, e84206.

Tallini, G., Vanni, R., Manfioletti, G., Kazmierczak, B., Faa, G., Pauwels, P., Bullerdiek, J., Giancotti, V., Van Den Berghe, H., and Dal Cin, P. (2000). HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. *Lab. Invest.* 80, 359–369.

Tam, R.Y., Yockell-Lelièvre, J., Smith, L.J., Julian, L.M., Baker, A.E.G., Choey, C., Hasim, M.S., Dimitroulakos, J., Stanford, W.L., and Shoichet,

M.S. (2019). Rationally designed 3D hydrogels model invasive lung diseases enabling high-content drug screening. *Adv. Mater.* 31, e1806214.

Taveira-DaSilva, A.M., and Moss, J. (2015). Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis. *Clin. Epidemiol.* 7, 249–257.

Tyburczy, M.E., Dies, K.A., Glass, J., Camposano, S., Chekaluk, Y., Thorne, A.R., Lin, L., Krueger, D., Franz, D.N., Thiele, E.A., et al. (2015). Mosaic and intronic mutations in TSC1/TSC2 explain the majority of TSC patients with No mutation identified by conventional testing. *PLoS Genet.* 11, e1005637.

Van Sluyters, R.C., Ballinger, B., Bayne, K., Cunningham, C., Degryse, A.-D., Dubner, R., Evans, H., Gdowski, M.J., Knight, R., Mench, J., et al. (2003). Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research (National Academies Press (US)).

Wuidart, A., Ousset, M., Rulands, S., Simons, B.D., Van Keymeulen, A., and Blanpain, C. (2016). Quantitative lineage tracing strategies to resolve multipotency in tissue-specific stem cells. *Genes Dev.* 30, 1261–1277.

Yamauchi, Y., Abe, K., Mantani, A., Hitoshi, Y., Suzuki, M., Osuzu, F., Kuratani, S., and Yamamura, K. (1999). A novel transgenic technique that allows specific marking of the neural crest cell lineage in mice. *Dev. Biol.* 212, 191–203.

Yao, J., Taveira-DaSilva, A.M., Jones, A.M., Julien-Williams, P., Stylianou, M., and Moss, J. (2014). Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. *Am. J. Respir. Crit. Care Med.* 190, 1273–1282.

Yu, J., and Henske, E.P. (2010). mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis. *Lymphat. Res. Biol.* 8, 43–49.

Yu, J.J., Robb, V.A., Morrison, T.A., Ariazi, E.A., Karbowiczek, M., Astrinidis, A., Wang, C., Hernandez-Cuevas, L., Seeholzer, L.F., Nicolas, E., et al. (2009). Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. *Proc. Natl. Acad. Sci. U S A* 106, 2635–2640.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Mouse monoclonal anti-CD57	Santa Cruz Biotechnology	Cat# sc-6261; RRID: AB_627130
Donkey anti-mouse IgG Alexa Fluor 488	Thermo Fisher Scientific	Cat# A21202; RRID:AB_141607
Chemicals, Peptides, and Recombinant Proteins		
DMEM/F12 (1:1)	Thermo Fisher Scientific	Cat# 11320033
EmbryoMax DMEM - High Glucose, Low Bicarbonate without sodium pyruvate	Millipore Sigma	Cat# SLM-220-M
ESGRO Leukemia Inhibitory Factor (LIF)	Millipore Sigma	Cat# ESG1106
Fetal bovine serum (FBS)	GE Healthcare Biosciences	Cat# SH30071.03
EmbryoMax ES Fetal Bovine Serum	Millipore Sigma	Cat# ES-009-C
Penicillin-Streptomycin	Thermo Fisher Scientific	Cat#15140122
Collagenase I	Worthington Biochemicals	Cat# LS004196
DNase I	Millipore Sigma	Cat# 4716728001
Elastase	Worthington Biochemicals	Cat# LS002294
Normal Donkey Serum	Sigma-Aldrich	Cat# D9663
Sodium Azide	Sigma-Aldrich	Cat# S2002
DRAQ5	Biolegend	Cat# 424101
Isoflurane	Henry Schein	Cat# 1311758
RBC Lysis Buffer	Santa Cruz Biotechnology	Cat# sc-296258
Sytox Green Nucleic Acid Stain	Thermo fisher Scientific	Cat# S7020
DAPI	Thermofisher Scientific	Cat# D1306
β -mercaptoethanol	Thermofisher Scientific	Cat# O34461
Sodium Pyruvate	Thermofisher Scientific	Cat# 11-360-070
L-Glutamine	Millipore Sigma	Cat# G7513
Minimum essential media nonessential amino acids (MEM NEAA)	Thermofisher Scientific	Cat# 11095080
Basic fibroblast growth factor (bFGF)	Millipore Sigma	Cat# GF003
Triton X-100	Thermofisher Scientific	Cat# BP151-500
Bovine Serum Albumin	Millipore Sigma	Cat# A8412
Normal Donkey Serum	Millipore Sigma	Cat# D9663
Prolong Diamond Anti-fade Mountant with DAPI	Thermofisher Scientific	Cat#P36971
Critical Commercial Assays		
RNeasy Mini Kit	Qiagen Inc.	Cat# 74106
High-Capacity cDNA Reverse Transcription Kit	Thermo Fisher Scientific	Cat# 4368813
QIAamp DNA Mini Kit	Qiagen Inc.	Cat# 51304
Deposited data		
Original data for Figures 2J–2S	Mendeley	https://doi.org/10.17632/tsjk7wm5s8.1#file-7f9e656d-e11b-4ab4-be87-6e99139b3ab9
Experimental Models: Cell Lines		
STO Feeder Cell Line	ATCC	Cat# CRL:1503 RRID:CVCL_3420

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Experimental Models: Organisms/Strains		
Mus musculus: B6.Cg-Gt(ROSA)26Sor ^{tm9(CAG-tdTomato)Hze/J}	The Jackson Laboratory	Cat# JAX:007909 RRID:IMSR_JAX:007909
Mus musculus: B6N.FVB-Tg(Mpz-Cre)26Mes/J	The Jackson Laboratory	Cat# JAX:017927 RRID:IMSR_JAX:017927
Mus musculus: B6. Cg-Mpz(Cre) ^{tm1.1JDar}	This paper	N/A
Mus musculus: B6.129S4-Tsc2 ^{tm1Djk/J} Mus musculus	The Jackson Laboratory	Cat# JAX:004686 RRID:IMSR_JAX:004686
Mus musculus: C57Bl/6J	The Jackson Laboratory	Cat# JAX:000664 RRID:IMSR_JAX:000664
Oligonucleotides		
Primer: R26R - Forward	AAAGTCGCTCTGAGTTGTTAT	N/A
Primer: R26R - Reverse	GGAGCGGGAGAAATGGATATG	N/A
Primer: Mpz - Forward	CCACCACCTCTCCATTGCAC	N/A
Primer: Mpz - Reverse	ATGTTTAGCTGGCCCAAATG	N/A
Primer: Tsc2 - Forward	CAAACCCACCTCCTCAAGCTTC	N/A
Primer: Tsc2 - Reverse	AGACTGCCTTGGGAAAAGCG	N/A
Tsc2 (Mm00442004_m1)	ThermoFisher Scientific	Cat# 4331182
CD57 (B3gat1) (Mm00661498_m1)	ThermoFisher Scientific	Cat# 4331182
Tfap2aα (Mm00495574_m1)	ThermoFisher Scientific	Cat# 4331182
Ngfr (Mm00446296_m1)	ThermoFisher Scientific	Cat# 4331182
Sox10 (Mm00569909)	ThermoFisher Scientific	Cat# 4331182
Software and Algorithms		
Prism 9 (version 9.11)	GraphPad Software	https://www.graphpad.com/scientific-software/prism/
VEVOLab 4.1	Visualsonics	https://www.visualsonics.com/product/software/vevo-lab
Paravision 6.0	Bruker	https://www.bruker.com/service/support-upgrades/software-downloads/mri.html
Living Image version 4.5	Perkin Elmer	https://www.perkinelmer.com/product/li-software-for-spectrum-1-seat-add-on-128113
GeneAmp 7900 SDS software	ThermoFisher Scientific	https://www.thermoFisher.com/order/catalog/product/4350490#/4350490

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jeanine D'Armiento (jmd12@cumc.columbia.edu).

Materials availability

This study did not generate new unique reagents.

Data and code availability

Original data for Figures 3A–3J in the paper is available (Mendeley Data DOI: <https://doi.org/10.17632/tjsk7wm5s8.1#file-7f9e656d-e11b-4ab4-be87-6e99139b3ab9>)

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mouse genetic studies

Animal experimentation was performed according to the Declaration of Helsinki convention for the use and care of animals and approved by the Institutional Animal Care and Use Committee (IACUC) at Columbia University Medical Center under protocol #AC-AAAR3401. The tuberous sclerosis *Tsc2*^{+/-} transgenic

reporter mice was generated by crossing floxed B6.Cg-Gt(ROSA)26Sor^{tm9(CAG-tdTomato)Hze}/J reporter mice (JAX #007909, RRID:IMSR_JAX:007909) (female, N = 10 animals, 10 weeks old) with transgenic B6N.FVB-Tg(Mpz-Cre)26Mes/J mice (JAX #017927, RRID:IMSR_JAX:017927) (male, N = 10 animals; 10 weeks old) encoding a cell adhesion molecule myelin protein zero (P₀) promoter driving expression of cre recombinase specifically in neural crest and Schwann cells (Kaku et al., 2012; Sowa et al., 2013; Yamauchi et al., 1999). These mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and maintained on a C57BL/6J background. B6. Cg-Mpz(Cre)^{tm1.1JDar} progeny (male/female, N = 8 animals), obtained after backcrosses (N > 5) to R26 mice, were then bred with tuberous sclerosis *Tsc2*^{+/-} mice (RRID:IMSR_JAX:004686) (male/female, 10 weeks old, N = 10 animals) containing a neo-cassette targeted disruption of the second coding exon in the *Tsc2* gene (Onda et al., 1999). Following F1 hybrid crosses of *Tsc2*^{+/-}/Mpz(Cre)/TdT^{fl/+} mice and genotyping analysis, *Tsc2*^{+/-}/Mpz(Cre)/TdT^{fl/fl} (male/female, N = 22 animals), *Tsc2*^{+/-}/Mpz(Cre)/TdT^{+/+} (male/female, N = 13 animals), *Tsc2*^{+/+}/Mpz(Cre)/TdT^{fl/fl} (male/female, N = 15 animals), and control *Tsc2*^{+/+}/Mpz(Cre)/TdT^{+/+} (male/female, N = 12 animals) mice development was monitored for 16 months and sacrificed for experiments. A schematic of genetic crosses involved in the development of this mouse model is displayed in Figure 1A. Tracking of spontaneous renal tumor development in all mouse genotypes commenced at 2 months of age, using tumor tracking protocols described below.

All mouse genotypes were confirmed by Southern hybridization of genomic DNA prepared from tail biopsies. Mouse sample sizes for each genotype utilized in this study are adequate to measure *Tsc2*^{+/-}-induced tumorigenesis detectable by tdTomato expression of neural crest cells expressing the Cre recombinase under the control of *Mpz* promoter, in comparison to mouse progeny wildtype for *Tsc2* and non-transgenic R26R mice. Given the time required for tumors to develop in the *Tsc2*^{+/-} mice, the 80-90% rate of spontaneous tumorigenesis in the kidneys and liver, the number of pups per litter (~7 pups), the number of pups per litter yield for each genotype, the isogenicity of strains specified for genetic crosses, and comparative studies between mouse genotypes, such an assumption can be made for the four genotypes being compared, using mouse attrition rate of 8%, statistical power of 0.8 with double-sided α error of 0.05 (Festing and Altman, 2002). Blinding was assured in this study because mouse genetic crosses to obtain desired genotypes, assessments of resulting phenotypes, and selection of mice for comparative imaging studies, were all performed by an independent laboratory technician without knowledge of the hypothesis being tested. Genotyping results determined assignments of mouse pups to the different genetic backgrounds. Inbred littermates were used in each mouse genotype category and mice were age- and sex-matched for each group. Mouse littermates were also selected for genetic crosses at random. All attempts at replication in this study yielded successful reproducibility 90% of the time. All tumor tracking, measurement and excision experiments were repeated 2-3 times on different days per age group.

METHOD DETAILS

Tumor tracking protocols

Non-invasive monitoring of renal tumor development in the TS reporter mouse was performed by sequential IVIS spectral imaging, small animal ultrasound and confirmatory magnetic resonance imaging (MRI) as described below. Tumor monitoring began at 2 months of age with biweekly intervals up to 16 months of age. All animal imaging, data acquisition and analysis was performed at the Oncology and Precision Therapeutics and Imaging Core (OPTIC) of the Columbia University Medical Center in accordance with the guidance of the Institutional Animal Care and Use Committee.

Biofluorescence imaging. Mice were anesthetized with inhaled 2.5% isoflurane (Cat# 1311758, IsoThesia™, Henry Schein, Melville, NY), and the abdomen of the animal was fully shaved using electric shears and depilatory cream (Nair™ Church & Dwight Co. Trenton, NJ). Mice were then positioned supine on the warming stage of the In Vivo Imaging System (IVIS) Spectrum (Perkin Elmer, Santa Clara, CA) directly facing the camera sensor to monitor heart rate and body temperature, and capture fluorescence images. *In vivo* imaging system parameters were determined using standard optimization protocols with spectral unmixing. Each IVIS imaging procedure was completed within 5-10 minutes; animals were monitored until fully recovered from anesthesia. Fluorescence images were analyzed and total radiant efficiency ([photons/s]/[μW/cm²]) calculated using the Living Image version 4.5 software (Perkin Elmer, Santa Clara, CA).

High frequency ultrasound imaging. Animals were anesthetized with 2.5% isoflurane (IsoThesia™, Henry Schein, Melville, NY) and placed on an electric heating pad to prevent hypothermia; abdominal hair was removed as described. Animals were positioned supine to monitor heart rate and body temperature.

Images of renal sagittal sections were obtained using the VisualSonics Vevo® 2100 Imaging System with 550D scan head (FUJIFILM VisualSonics Inc., Toronto, ON) at 55 megahertz. The 3-D Mode was used for advanced data acquisition and analysis, with virtual sections obtained in all directions (x-, y-, z- and other plane variations). Each ultrasound was completed within 10–15 minutes; animals were monitored until fully recovered from anesthesia. Ultrasound images were analyzed using the VEVOLab 4.1 software provided by Visualsonics (Toronto, ON).

Magnetic Resonance Imaging (MRI). The MRI examination of the abdomen of the mice was performed to confirm findings of ultrasound scans in some experimental mice. MRI was performed with a 9.4 Tesla animal scanner (Bruker BioSpin, Germany). Animals were anesthetized by inhalation of isoflurane (IsoThesia™, Henry Schein, Melville, NY) (3% induction and 1–2% maintenance) and were kept homeothermic by a water-circulating system to keep the MRI bed at 37°C. A Rapid Imaging with Refocused Echoes sequence was used to acquire multi-slice images in the long axis of both kidneys by using the following parameters: TR/TE = 2600/30 ms, averages = 4, RARE factor = 8, matrix = 256x256, field of view = 40x40 mm², slice thickness = 0.5 mm. MRI images were analyzed utilizing the Paravision 6.0 software from Bruker BioSpin.

Mouse renal tumor processing and flow cytometry

Individual renal tumor length and width per kidney pair per mice were measured using digital calipers following mice sacrifice. Tumor volumes were estimated using the formula: (Width² X Length)/2 (Faustino-Rocha et al., 2013; Sápi et al., 2015). Renal tumor and tissues biopsied from *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl}, *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{+/-}, *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl}, and control *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{+/-} mice at 4, 6, 12, and 16 months were pooled by age group and digested into single cell suspension (Neelisetty et al., 2015). Samples were minced in DMEM-F12 media supplemented with 2% fetal bovine serum (FBS) (#SH30071.03, Hyclone, GE Healthcare Biosciences, Piscataway, NJ) using fine sterile razors and digested with a cocktail of collagenase I (170mg/L, Cat# LS004196, Worthington Biochemical, Lakewood, NJ), DNase I (0.33 U/ml; Cat# 4716728001, Millipore Sigma, St. Louis, MO) and elastase (0.075 U/ml, Cat# LS002294, Worthington Biochemical, Lakewood, NJ) in a shaker at a speed of 85rpm at 37°C for 45 mins. Tissue particles were vigorously triturated and re-incubated in the same conditions for another 30 mins then passed through 100µm, 70µm, and 40µm cell strainers sequentially. Cell suspensions were centrifuged for 5 min at 300 x g at room temperature, supernatant aspirated, and the erythrocytes lysed using 1x RBC lysis buffer (Cat# sc-296258, Santa Cruz Biotechnology, Dallas, TX) for 10 mins. Following subsequent centrifugation for 5 min at 300 x g, cell pellets were resuspended in PBS containing 2% FBS and DAPI (Cat# D1306, ThermoFisher Scientific, Grand Island, NY) or Sytox green viability dye (Cat# S7020, ThermoFisher Scientific, Grand Island, NY) in the dark for 10 mins. Cells were washed in cold PBS, filtered with 40µm cell strainer, and resuspended in PBS containing 2% FBS, DNase I for cell sorting, and DRAQ5 (1:1000, Cat# 424101, BioLegend, San Diego, CA) in some experiments to distinguish viable cells. Flow cytometry was performed using a BD FACS Aria II (Becton Dickinson, Franklin Lakes, NJ, USA) at the Columbia Stem Cell Initiative (CSCI) Flow Cytometry Core Facility and cells were sorted into tubes pre-incubated with DMEM-F12 containing 2% FBS. Single cells were sequentially selected on FSC-A/SSC-A and FSC-A/FSC-H dot plots and band-pass filters 586/15, 530/30, 450/50, or 715/50 were used to acquire tdTomato and viability dye signals. Tubes with unstained cells were used to set compensation and at least 50,000 events were collected for each tumor or tissue sample sorted into tdTomato⁽⁺⁾ vs tdTomato⁽⁻⁾ fractions per experiment. Data analysis was performed using FlowJo 10.7.1 (BD Biosciences, Franklin Lakes, NJ) or FCS Express 7 Plus (De Novo Software, Glendale, CA).

Neural crest cell culture

Cranial (CNCC) and trunk (TNCC) neural crest cells were used as positive comparative controls for flow cytometry and RT-qPCR experiments. These tissues were obtained from 9.5dpc *Tsc2*^{+/-}/*Mpz*(Cre)/*TdT*^{fl/fl} fetal mice excavated from pregnant dam. Isolation of CNCCs was performed by cutting a region between head fold and the anterior tip of the otic placode of mouse embryos (Au - Gonzalez Malagon et al., 2019) under a dissecting microscope, while TNCCs were obtained by excising embryonic neural tube between somites 16–22 (Pfaltzgraff et al., 2012). Tissue dissects were placed in the center of sterile matrigel-coated petri dishes containing neural crest media and incubated at 37°C in 5% CO₂ to allow for migration of NCCs away from the neural tube. NCC media was conditioned using STO feeder cells (mouse embryonic fibroblasts) (ATCC Cat# CRL-1503, RRID:CVCL_3420) grown overnight in Dulbecco's modified Eagle's medium (DMEM, 4500mg/L glucose) (Cat# SLM-220-M, Millipore Sigma, St. Louis, MO) containing 15% fetal bovine serum (FBS) (Cat# ES-009-C, Millipore Sigma, St. Louis, MO), 0.1mM minimum essential media nonessential amino acids (MEM NEAA 100X) (Cat# 11095080), 1 mM sodium pyruvate (Cat# 11-360-070, ThermoFisher

Scientific, Grand Island, NY), 55 μ M β -mercaptoethanol (Cat# O34461-100, Thermofisher Scientific, Grand Island, NY), 100 units/mL penicillin-streptomycin (Cat#15140122, Thermofisher Scientific, Grand Island, NY) and 2 mM L-glutamine (Cat# G7513, Millipore Sigma, St. Louis, MO). Conditioned media was thereafter supplemented with basic fibroblast growth factor (bFGF, 25ng/ml) (Cat# GF003, Millipore Sigma, St. Louis, MO) and leukemia inhibition factor (LIF, 1000U) (Cat# ESG1106, Millipore Sigma, St. Louis, MO). 48hrs after NCC migration from neural tube, explant tissue is removed and NCCs routinely passaged. NCCs were incubated in DAPI viability dyes for 10 mins prior to flow cytometry experiments.

Immunohistochemistry. Renal tumor and tissues of differentially aged mice were excised, briefly washed in PBS and immediately fixed in 4% paraformaldehyde (PFA) for 2 hours at room temperature. Renal tumors and tissues are then rinsed in PBS and incubated overnight at 4°C in 30% sucrose to preserve endogenous protein expression (Wuidart et al., 2016). Thereafter, fixed tissues/tumors were immediately embedded in OCT compound, snap-frozen in isopentane mixed with dry ice and kept at -80°C. Embedded tissues were used to obtain 4 μ m thick sections at the Molecular Pathology Core Facility at Columbia University Medical Center.

For CD57 (β -1,3-glucuronyltransferase (B3GAT1)) immunolabeling (sc-6261; RRID: AB_627130; Santa Cruz Biotechnologies, Dallas, TX), tissue/tumor slices were blocked and permeabilized for 1 hour at room temperature using a mixture of 0.3% Triton X-100 (Cat# BP151-500, Thermofisher Scientific, Grand Island, NY), 1% bovine serum albumin (BSA) (Cat# 8412, Millipore Sigma, St. Louis, MO) and 10% normal donkey serum (NDS) (Cat# D9663, Millipore Sigma, St. Louis, MO), and incubated overnight at 4°C in anti-CD57 diluted in antibody dilution buffer (1% BSA, 1% NDS, 0.3% Triton X-100, 0.01% sodium azide). Following 1-hr secondary antibody incubation using donkey anti-mouse Alexa Fluor 488 (Cat# A21202, RRID:AB_141607, Thermofisher Scientific, Grand Island, NY), slides were cover-slipped using Prolong Diamond Anti-fade Mountant with DAPI (Cat# P36971, Thermofisher Scientific, Grand Island, NY) and visualized using Ti-E Eclipse inverted fluorescent or confocal microscope (Nikon Instruments Inc., Melville, NY). Immunohistochemistry experiments were repeated twice for each aged mice timepoint using N=3 slides per tissue/tumor, 2-3 sections per slide. The use of mouse tissue samples was approved by the IACUC protocol #AC-AAAR3401.

RT-qPCR and southern blot. Total RNA was isolated from mouse renal tumors and tissue biopsies excised from all mouse genotypes. RNA isolation was performed using RNeasy Mini Kit (#74106, Qiagen Inc., Valencia, CA). High-quality RNA was ensured by UV spectroscopy and incorporating DNase treatment in the protocol. Reverse transcription was performed using the High-Capacity cDNA Reverse Transcription Kit (#4368813; Applied Biosystems, Thermofisher Scientific, Grand Island, NY, USA) (Qin et al., 2011). Quantification of gene expression was assessed in quadruplicates per biological replicate by reverse transcription qPCR using TaqMan probes with FAM dye labels (Thermofisher Scientific, Grand Island, NY), mouse primers for *Tsc2* (Mm00442004_m1), *B3gat1* (Mm00661498_m1), *Tfap2a* (Mm00495574_m1), *Ngfr* (Mm00446296_m1) and *Sox10* (Mm00569909) (Cat# 4331182, Thermofisher Scientific, Grand Island, NY). The ABI 7300 real-time sequence detection system (Applied Biosystems, Thermofisher Scientific, Grand Island, NY) was used along with the GeneAmp 7900 SDS software (Cat# 4350490, Applied Biosystems, Thermofisher Scientific, Grand Island, NY) to convert data into threshold cycle ($\Delta\Delta$ Ct) values.

For genotyping studies, DNA was isolated from mice tail snips collected in sterile 1.5ml microcentrifuge tubes by digestion in 50mM Tris, pH 8.0, 100mM ethylenediaminetetraacetic acid (EDTA) (Cat# 17892, Thermofisher Scientific, Grand Island, NY), 0.5% sodium dodecyl sulfate (SDS) (Cat# L3771, Millipore Sigma, St. Louis, MO) and 20mg/ml proteinase K (Cat# AM2548, Thermofisher Scientific, Grand Island, NY). After overnight incubation, a phenol:chloroform (1:1) phase separation was performed, and DNA precipitated from the aqueous layer using a sodium acetate and ethanol mixture. DNA solubilized in TE buffer (10mM Tris, pH 8.0, 1mM EDTA) was further resolved on 1.2-2.7% agarose gel and probe hybridization performed using the following cDNA primer sequences: *R26R* 5'-AAAGTCGCTCTGAGTTGTAT-3' (forward) and 5'-GGAGCGGGAGAAATGGATATG-3' (reverse); *Mpz* transgene 5'-CCACCACCTCTCCATTGCAC-3' (forward) and 5'-ATGTTAGCTGGCCCAAATG-3' (reverse); *Tsc2* 5'-CAAACCCACCTCCTCAAGCTTC-3' (forward) and 5'-AGACTGCCTTGGGAAAA GCG-3' (reverse) (Integrated DNA Technologies, Research Triangle Park, NC).

QUANTIFICATION AND STATISTICAL ANALYSIS

This investigation was utilized as a pilot study to trace the ontogeny of tumorigenic cells in the *Tsc2*^{+/-} mice; therefore, the less rigorous resource equation method and upper confidence limit (UCL) approach was

employed to estimate optimal sample size for mouse groups in this pilot study (Festing, 2006). The time required for tumors to develop in *Tsc2*^{+/-} mice was considered, as well as the 80-90% rate of spontaneous tumorigenesis in the kidneys, the number of pups per litter yield (~7 pups), the total number of litters per genotype used, the isogeneity of strains specified for genetic crosses, mouse attrition rate of 8%, and statistical power of 0.8 with double-sided α error of 0.05 (Festing and Altman, 2002; Van Sluyters et al., 2003). Sample sizes in experiments are specified in each figure legend, and all data in the text and figures are expressed as mean $\pm$ SEM. Statistical tests are appropriately justified and performed using a one-way ANOVA with post-hoc Dunnett tests comparing treatment conditions to controls where applicable.